Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Malignant Lymphoma

  Free Subscription

Articles published in Leuk Lymphoma

Retrieve available abstracts of 583 articles:
HTML format

Single Articles

    July 2021
  1. DURANI U, Ansell SM
    CD5+ diffuse large B-cell lymphoma: a narrative review.
    Leuk Lymphoma. 2021 Jul 21:1-9. doi: 10.1080/10428194.2021.1953010.
    PubMed     Abstract available

  2. BAEK GT, Mathis NJ, Perissinotti AJ, Marini BL, et al
    Late-onset complications with bendamustine versus CHOP or CVP based chemoimmunotherapy in indolent Non-Hodgkin's lymphoma.
    Leuk Lymphoma. 2021 Jul 15:1-9. doi: 10.1080/10428194.2021.1953014.
    PubMed     Abstract available

  3. SONG Y, Li J, Wang S, Zhou Z, et al
    The promising outcome with simultaneous integrated boost intensity modulated radiotherapy in confined nasal extranodal NK/T-cell lymphoma.
    Leuk Lymphoma. 2021 Jul 14:1-8. doi: 10.1080/10428194.2021.1948035.
    PubMed     Abstract available

  4. LAPIERRE L, Pericart S, Protin C, Borel C, et al
    Nivolumab in refractory cerebral relapse of Hodgkin's lymphoma.
    Leuk Lymphoma. 2021 Jul 13:1-3. doi: 10.1080/10428194.2021.1950711.

  5. ALLIOUX F, Gandhi D, Vilque JP, Nganoa C, et al
    End-of-treatment (18)F-FDG PET/CT in diffuse large B cell lymphoma patients: DeltaSUV outperforms Deauville score.
    Leuk Lymphoma. 2021 Jul 5:1-9. doi: 10.1080/10428194.2021.1948028.
    PubMed     Abstract available

  6. WITTMANN DAYAGI T, Sherman G, Bielorai B, Adam E, et al
    Characteristics and risk factors of infections following CD28-based CD19 CAR-T cells.
    Leuk Lymphoma. 2021;62:1692-1701.
    PubMed     Abstract available

  7. MANSO R, Rodriguez-Perales S, Torres-Ruiz R, Santonja C, et al
    PD-L1 expression in peripheral T-cell lymphomas is not related to either PD-L1 gene amplification or rearrangements.
    Leuk Lymphoma. 2021;62:1648-1656.
    PubMed     Abstract available

    June 2021
  8. MOU E, Falchi L, Sundaram V, Abramson JS, et al
    Impact of initial biopsy type on the time to final diagnostic biopsy in patients with follicular lymphoma and suspected histologic transformation.
    Leuk Lymphoma. 2021 Jun 26:1-9. doi: 10.1080/10428194.2021.1941936.
    PubMed     Abstract available

  9. XIAO Z, Mo Y, Long W, Li R, et al
    Value of baseline and end of chemotherapy (18)F-FDG PET/CT in pediatric patients with Burkitt lymphoma.
    Leuk Lymphoma. 2021 Jun 24:1-9. doi: 10.1080/10428194.2021.1941933.
    PubMed     Abstract available

  10. ELGAAFARY S, Lopez C, Nagel I, Vater I, et al
    Molecular characterization of Burkitt lymphoma in the breast or ovary.
    Leuk Lymphoma. 2021 Jun 24:1-10. doi: 10.1080/10428194.2021.1907374.
    PubMed     Abstract available

  11. OU YC, Tang Z, Novotny W, Cohen A, et al
    Rationale for once-daily or twice-daily dosing of zanubrutinib in patients with mantle cell lymphoma.
    Leuk Lymphoma. 2021 Jun 23:1-13. doi: 10.1080/10428194.2021.1929961.
    PubMed     Abstract available

  12. CASTILLO JJ, Beltran BE, Malpica L, Marques-Piubelli ML, et al
    Anaplastic lymphoma kinase-positive large B-cell lymphoma (ALK + LBCL): a systematic review of clinicopathological features and management.
    Leuk Lymphoma. 2021 Jun 21:1-9. doi: 10.1080/10428194.2021.1941929.
    PubMed     Abstract available

  13. HUSBY S, Favero F, Rodriguez-Gonzalez FG, Sutton LA, et al
    Mutations known from B-cell lymphoid malignancies are not found in CD34(+) stem cells from patients with lymphoma.
    Leuk Lymphoma. 2021 Jun 21:1-4. doi: 10.1080/10428194.2021.1933473.

  14. MESSMER M, Wagner-Johnston N
    COVID-19 vaccination in patients on rituximab: a survey of lymphoma physicians at NCI designated cancer centers.
    Leuk Lymphoma. 2021 Jun 21:1-4. doi: 10.1080/10428194.2021.1941939.

  15. CHIHARA D, Larson MC, Robinson DP, Thompson CA, et al
    Body mass index and survival of patients with lymphoma.
    Leuk Lymphoma. 2021 Jun 14:1-8. doi: 10.1080/10428194.2021.1929956.
    PubMed     Abstract available

  16. KARALEXI MA, Pourtsidis A, Panagopoulou P, Moschovi M, et al
    Overall and event-free survival of childhood lymphoma in Greece: analysis of harmonized clinical data over a 24-year active registration period.
    Leuk Lymphoma. 2021 Jun 11:1-13. doi: 10.1080/10428194.2021.1907376.
    PubMed     Abstract available

  17. MOZESSOHN L, Zhang L, Odejide OO, Chen R, et al
    Prognostic value of disease risk score versus gait speed in older adults with lymphoma.
    Leuk Lymphoma. 2021 Jun 11:1-8. doi: 10.1080/10428194.2021.1938029.
    PubMed     Abstract available

  18. BRAM EDNERSSON S, Stern M, Fagman H, Nilsson-Ehle H, et al
    Proteomic analysis in diffuse large B-cell lymphoma identifies dysregulated tumor microenvironment proteins in non-GCB/ABC subtype patients.
    Leuk Lymphoma. 2021 Jun 11:1-14. doi: 10.1080/10428194.2021.1913147.
    PubMed     Abstract available

  19. MINSON A, Dickinson M
    Too much, or not enough? The enduring uncertainty of maintenance rituximab for transformed follicular lymphoma.
    Leuk Lymphoma. 2021 Jun 9:1-3. doi: 10.1080/10428194.2021.1938033.

  20. SORIGUE M, Sancho JM
    The lymphocyte-to-monocyte ratio in follicular lymphoma.
    Leuk Lymphoma. 2021 Jun 8:1-4. doi: 10.1080/10428194.2021.1929965.

  21. CHEN Q, Liu S, Zhang K, Yu B, et al
    Hsa-miR-372-5p regulates the NIMA related kinase 7 and IL-1beta release in NK/T-cell lymphoma.
    Leuk Lymphoma. 2021 Jun 3:1-9. doi: 10.1080/10428194.2021.1933472.
    PubMed     Abstract available

  22. RODRIGUES JM, Porwit A, Hassan M, Ek S, et al
    Targeted genomic investigations in a population-based cohort of mantle cell lymphoma reveal novel clinically relevant targets.
    Leuk Lymphoma. 2021 Jun 3:1-11. doi: 10.1080/10428194.2021.1933480.
    PubMed     Abstract available

  23. TREVINO KM, Martin P, Saracino R, Leonard JP, et al
    Unmet need for mental health services in indolent lymphoma: age differences over one-year post-diagnosis.
    Leuk Lymphoma. 2021;62:1370-1378.
    PubMed     Abstract available

  24. MOZAS P, Lopez-Guillermo A
    Response to: The lymphocyte-to-monocyte ratio in follicular lymphoma.
    Leuk Lymphoma. 2021 Jun 1:1-2. doi: 10.1080/10428194.2021.1933482.

  25. ALVAREZ E, Le T, Kahn J, Winestone L, et al
    Comorbidities and socioeconomic status are predictors of survival in children and young adults with Burkitt lymphoma.
    Leuk Lymphoma. 2021 Jun 1:1-7. doi: 10.1080/10428194.2021.1932873.

    May 2021
  26. FLORINDEZ JA, Alderuccio JP, Reis IM, Lossos IS, et al
    Primary thyroid lymphoma: survival analysis of SEER database (1995-2016).
    Leuk Lymphoma. 2021 May 27:1-4. doi: 10.1080/10428194.2021.1933479.

  27. ZHU X, Li W, Zhu J, Chen H, et al
    Influence of MTHFR C677T and A1298C polymorphisms on the survival of pediatric patients with non-Hodgkin lymphoma.
    Leuk Lymphoma. 2021 May 25:1-9. doi: 10.1080/10428194.2021.1927017.
    PubMed     Abstract available

  28. PALOMBA ML, Jun MP, Lymp J, Nguyen A, et al
    Postinfusion monitoring costs by site of care for patients with relapsed/refractory large B-cell lymphoma receiving third- or later-line treatment with lisocabtagene maraleucel in the TRANSCEND NHL 001 and OUTREACH trials.
    Leuk Lymphoma. 2021 May 21:1-8. doi: 10.1080/10428194.2021.1910686.
    PubMed     Abstract available

  29. BONZHEIM I, Quintanilla-Martinez L
    All activated signaling pathways lead to anaplastic large cell lymphoma (ALCL).
    Leuk Lymphoma. 2021 May 21:1-3. doi: 10.1080/10428194.2021.1924373.

  30. LIANG D, Wei C, Zhang X, Yang J, et al
    Efficacy of lenalidomide for relapsed or refractory T lymphoblastic lymphoma/leukemia after allogeneic hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2021 May 17:1-5. doi: 10.1080/10428194.2021.1919665.

  31. CHAPMAN J, Verdun RE, Lossos IS
    Low LIM-domain only 2 (LMO2) expression in aggressive B cell lymphoma correlates with MYC and MYC/BCL2 rearrangements, especially in germinal center cell-type tumors.
    Leuk Lymphoma. 2021 May 14:1-4. doi: 10.1080/10428194.2021.1927020.

  32. FAKHRI B, Yilmaz E, Gao F, Ambinder RF, et al
    Survival after autologous versus allogeneic transplantation in patients with relapsed and refractory Hodgkin lymphoma.
    Leuk Lymphoma. 2021 May 14:1-8. doi: 10.1080/10428194.2021.1927016.
    PubMed     Abstract available

  33. MACHAN S, Rodriguez M, Alonso-Alonso R, Manso R, et al
    Subcutaneous panniculitis-like T-cell lymphoma, lupus erythematosus profundus, and overlapping cases: molecular characterization through the study of 208 genes.
    Leuk Lymphoma. 2021 May 8:1-11. doi: 10.1080/10428194.2021.1901098.
    PubMed     Abstract available

  34. YANG J, Zhang Y, Yang P, Zhang X, et al
    A novel nomogram based on prognostic factors for predicting venous thrombosis risk in lymphoma patients.
    Leuk Lymphoma. 2021 May 8:1-9. doi: 10.1080/10428194.2021.1913149.
    PubMed     Abstract available

  35. GOYAL RK, Jain P, Nagar SP, Le H, et al
    Real-world evidence on survival, adverse events, and health care burden in Medicare patients with mantle cell lymphoma.
    Leuk Lymphoma. 2021 May 8:1-10. doi: 10.1080/10428194.2021.1919662.
    PubMed     Abstract available

  36. AL FEGHALI KA, Fang P, Gule-Monroe M, Milgrom S, et al
    Prognostic value of disease distribution in secondary central nervous system diffuse large B cell lymphoma treated with radiation therapy.
    Leuk Lymphoma. 2021 May 4:1-8. doi: 10.1080/10428194.2021.1919656.
    PubMed     Abstract available

  37. LANG N, Kuruvilla J
    Evolving management strategies for lymphomas during the COVID-19 pandemic.
    Leuk Lymphoma. 2021;62:1046-1056.
    PubMed     Abstract available

  38. WAGNER-JOHNSTON ND, Schuster SJ, deVos S, Salles G, et al
    Outcomes of patients with up to 6 years of follow-up from a phase 2 study of idelalisib for relapsed indolent lymphomas.
    Leuk Lymphoma. 2021;62:1077-1087.
    PubMed     Abstract available

  39. SEKAR A, Davids MS
    Idelalisib in indolent NHL - has it finally found its niche?
    Leuk Lymphoma. 2021;62:1029-1030.

    April 2021
  40. LUCIJANIC M, Korunic RH, Sedinic M, Kusec R, et al
    Prognostic impact of psoas muscle index in patients with diffuse large B-cell lymphoma might be dependent on the immunochemotherapy type.
    Leuk Lymphoma. 2021 Apr 28:1-4. doi: 10.1080/10428194.2021.1919667.

  41. CARPIO C, Iacoboni G, Villacampa G, Catala E, et al
    Selection process and causes of non-eligibility for CD19 CAR-T cell therapy in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma in a European center.
    Leuk Lymphoma. 2021 Apr 24:1-4. doi: 10.1080/10428194.2021.1913141.

  42. GUPTA A, Gill S
    CAR-T cell persistence in the treatment of leukemia and lymphoma.
    Leuk Lymphoma. 2021 Apr 19:1-13. doi: 10.1080/10428194.2021.1913146.
    PubMed     Abstract available

  43. WILSON WH, Phillips T, Popplewell L, de Vos S, et al
    Phase 1b/2 study of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in patients with relapsed/refractory diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2021 Apr 15:1-16. doi: 10.1080/10428194.2021.1907371.
    PubMed     Abstract available

  44. OLLIKAINEN RK, Kotkaranta PH, Kemppainen J, Teppo HR, et al
    Different chemokine profile between systemic and testicular diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2021 Apr 15:1-10. doi: 10.1080/10428194.2021.1913150.
    PubMed     Abstract available

    March 2021
  45. EPSTEIN-PETERSON ZD, Ganesan N, Barker JN, Drullinsky PR, et al
    Outcomes of adult T-Cell leukemia/lymphoma with allogeneic stem cell transplantation: single-institution experience.
    Leuk Lymphoma. 2021 Mar 29:1-7. doi: 10.1080/10428194.2021.1897806.
    PubMed     Abstract available

  46. CAZELLES C, Belhadj K, Vellemans H, Camus V, et al
    Rituximab plus gemcitabine and oxaliplatin (R-GemOx) in refractory/relapsed diffuse large B-cell lymphoma: a real-life study in patients ineligible for autologous stem-cell transplantation.
    Leuk Lymphoma. 2021 Mar 25:1-8. doi: 10.1080/10428194.2021.1901090.
    PubMed     Abstract available

  47. URYU H, Mishima Y, Tsuyama N, Yokoyama M, et al
    Rituximab maintenance improves outcomes of transformed diffuse large B-cell lymphoma: a retrospective study of 519 cases with de novo diffuse large B-cell lymphoma and 62 cases with concurrent diffuse large B-cell lymphoma and follicular lymphoma.
    Leuk Lymphoma. 2021 Mar 21:1-10. doi: 10.1080/10428194.2021.1901091.
    PubMed     Abstract available

  48. BALAKRISHNA J, Basumallik N, Matulonis R, Scott D, et al
    Intensity of antigen expression reflects IGHV mutational status and Dohner-defined prognostic categories in chronic lymphocytic leukemia, monoclonal B-cell lymphocytosis, and small lymphocytic lymphoma.
    Leuk Lymphoma. 2021 Mar 18:1-12. doi: 10.1080/10428194.2021.1894641.
    PubMed     Abstract available

  49. WANG X, McIntosh L, Selove WJ, Zivny J, et al
    Pseudoprogression of triple-hit diffuse large B-cell lymphoma following polatuzumab vedotin-based salvage therapy.
    Leuk Lymphoma. 2021 Mar 15:1-4. doi: 10.1080/10428194.2021.1894646.

  50. GAO Y, Ding X
    miR-145-5p exerts anti-tumor effects in diffuse large B-cell lymphoma by regulating S1PR1/STAT3/AKT pathway.
    Leuk Lymphoma. 2021 Mar 13:1-8. doi: 10.1080/10428194.2021.1894642.
    PubMed     Abstract available

  51. SHIROUCHI Y, Yokoyama M, Fukuta T, Uryu H, et al
    Progression-free survival at 24 months as a predictor of survival outcomes after CHOP treatment in patients with peripheral T-cell lymphoma: a single-center validation study in a Japanese population.
    Leuk Lymphoma. 2021 Mar 10:1-12. doi: 10.1080/10428194.2021.1894649.
    PubMed     Abstract available

  52. MCCARTHY P, Harford J, O'Marcaigh A, Malone A, et al
    Ongoing excellent outcomes with reduced toxicities following integration of molecular targeted therapies in pediatric anaplastic large cell lymphoma.
    Leuk Lymphoma. 2021 Mar 8:1-5. doi: 10.1080/10428194.2021.1894644.

  53. TIAN Y, Li L, Lin G, Wang Y, et al
    lncRNA SNHG14 promotes oncogenesis and immune evasion in diffuse large-B-cell lymphoma by sequestering miR-152-3p.
    Leuk Lymphoma. 2021 Mar 8:1-15. doi: 10.1080/10428194.2021.1876866.
    PubMed     Abstract available

  54. FRECHET L, Woronoff AS, Gerazime A, Puzenat E, et al
    Primary cutaneous lymphoma: a population-based cancer registry descriptive study of 155 consecutive cases diagnosed between 1979 and 2016.
    Leuk Lymphoma. 2021 Mar 8:1-6. doi: 10.1080/10428194.2021.1891232.

  55. FANG X, Young KH
    Hepatitis B virus antibody status provides new insights in diffuse large B-Cell lymphoma.
    Leuk Lymphoma. 2021 Mar 2:1-4. doi: 10.1080/10428194.2021.1891233.

  56. ISSA DE, Dinmohamed AG, Wondergem MJ, Blommestein HM, et al
    A population-based study on different regimens of R-CHOP in patients with newly diagnosed DLBCL in The Netherlands.
    Leuk Lymphoma. 2021;62:549-559.
    PubMed     Abstract available

  57. BERNING P, Lenz G
    The role of PI3K inhibitors in the treatment of malignant lymphomas.
    Leuk Lymphoma. 2021;62:517-527.
    PubMed     Abstract available

    February 2021
  58. DANCE KV, Imbody CB, Chen L, McNeill L, et al
    Perceptions of clinical care and research among African-American patients with lymphoma.
    Leuk Lymphoma. 2021 Feb 28:1-13. doi: 10.1080/10428194.2021.1892092.
    PubMed     Abstract available

  59. LUAN D, Wu Y, Goldstein J, Rutherford S, et al
    Evaluation of the prognostic utility of bone marrow biopsy in diffuse large B-Cell lymphoma in the SEER-Medicare dataset.
    Leuk Lymphoma. 2021 Feb 25:1-14. doi: 10.1080/10428194.2021.1889540.
    PubMed     Abstract available

  60. NOEL N, Beaudonnet G, Cauquil C, Laurenge A, et al
    Inflammatory demyelinating polyneuropathies and lymphoma: clues to diagnosis and therapy.
    Leuk Lymphoma. 2021 Feb 24:1-9. doi: 10.1080/10428194.2021.1889535.

  61. SILVA O, Charu V, Ewalt MD, Metcalf RA, et al
    Classic Hodgkin lymphoma in Guatemalan children of age less than six years: analysis of immune regulatory pathways and the tumor microenvironment.
    Leuk Lymphoma. 2021 Feb 24:1-13. doi: 10.1080/10428194.2021.1885666.
    PubMed     Abstract available

  62. BINKLEY MS, Hiniker SM, Younes S, Yoo C, et al
    Stage I-II diffuse large B-cell lymphoma treated with rituximab and chemotherapy with or without radiotherapy.
    Leuk Lymphoma. 2021 Feb 23:1-15. doi: 10.1080/10428194.2021.1876859.
    PubMed     Abstract available

  63. YALAMANCHI M, Sharma A, Nguyen M, Truong J, et al
    Successful and durable response of primary CNS T-cell lymphoma to upfront temozolomide monotherapy.
    Leuk Lymphoma. 2021 Feb 21:1-5. doi: 10.1080/10428194.2021.1889538.

  64. DESAI S, Ansell SM
    Future directions in Hodgkin lymphoma: checkpoint inhibitors and beyond.
    Leuk Lymphoma. 2021 Feb 18:1-15. doi: 10.1080/10428194.2021.1885667.
    PubMed     Abstract available

  65. BONOMETTI A, Boveri E, Varettoni M, Ripamonti A, et al
    Systemic mastocytosis and lymphoplasmacytic lymphoma: an unusual and intriguing form of SM-AHN.
    Leuk Lymphoma. 2021 Feb 14:1-5. doi: 10.1080/10428194.2021.1885661.

  66. ORFALI N, Jhanwar Y, Koo C, Pasciolla M, et al
    Sequential intensive chemotherapy followed by autologous or allogeneic transplantation for refractory lymphoma.
    Leuk Lymphoma. 2021 Feb 13:1-15. doi: 10.1080/10428194.2021.1881516.
    PubMed     Abstract available

  67. SINATKAS V, Stathopoulou K, Xagoraris I, Ye J, et al
    MDMX/MDM4 is highly expressed and contributes to cell growth and survival in anaplastic large cell lymphoma.
    Leuk Lymphoma. 2021 Feb 11:1-11. doi: 10.1080/10428194.2021.1876871.
    PubMed     Abstract available

  68. ZHENG M, Zhou X, Wang Q, Chen X, et al
    Metabolomic approach to characterize the metabolic phenotypes and varied response to ouabain of diffuse large B-cell lymphoma cells.
    Leuk Lymphoma. 2021 Feb 10:1-18. doi: 10.1080/10428194.2021.1881513.
    PubMed     Abstract available

  69. MILGROM SA, Dabaja BS, Mikhaeel NG
    Advanced-stage Hodgkin lymphoma: have effective therapy and modern imaging changed the significance of bulky disease?
    Leuk Lymphoma. 2021 Feb 7:1-19. doi: 10.1080/10428194.2021.1881515.
    PubMed     Abstract available

  70. RAJAMAKI A, Sunela K, Prusila REI, Kuusisto MEL, et al
    Female patients with follicular lymphoma have a better prognosis if primary remission lasts over 24 months.
    Leuk Lymphoma. 2021 Feb 5:1-9. doi: 10.1080/10428194.2021.1872073.
    PubMed     Abstract available

    January 2021
  71. CAMPBELL BA, Khot A
    "RT or not RT?" The question for early-stage peripheral T-cell lymphoma.
    Leuk Lymphoma. 2021 Jan 29:1-4. doi: 10.1080/10428194.2021.1876873.

  72. JAIME-PEREZ JC, Hernandez-Coronado M, Picon-Galindo E, Salazar-Cavazos L, et al
    Results of a completely outpatient autologous stem cell transplant program for lymphoma patients receiving reduced-intensity conditioning.
    Leuk Lymphoma. 2021 Jan 24:1-10. doi: 10.1080/10428194.2021.1876870.
    PubMed     Abstract available

  73. AUGUSTYN A, Medeiros LJ, Ludmir EB, Gunther J, et al
    The impact of cell-of-origin, MYC/Bcl-2 dual expression and MYC rearrangement on disease relapse among early stage diffuse large B-cell lymphoma patients treated with combined modality therapy.
    Leuk Lymphoma. 2021 Jan 22:1-12. doi: 10.1080/10428194.2020.1869965.
    PubMed     Abstract available

  74. LOPEZ-ALONSO R, Qi S, Mashiach T, Weiler-Sagie M, et al
    The presence of a bulky mediastinal mass of 7 cm or greater in diameter confers an adverse prognosis to patients with advanced Hodgkin lymphoma in case of negative interim PET/CT.
    Leuk Lymphoma. 2021 Jan 22:1-18. doi: 10.1080/10428194.2021.1872069.
    PubMed     Abstract available

  75. MARQUES MO, Manso PG, Araujo RLC, Brito FDN, et al
    Long-term outcomes of ocular adnexal lymphomas: case series from two lymphoma centers in Brazil.
    Leuk Lymphoma. 2021 Jan 18:1-5. doi: 10.1080/10428194.2020.1855348.

  76. LYONS RM, Shtivelband M, Kingsley E, Moezi M, et al
    Efficacy and safety of ofatumumab and bendamustine followed by ofatumumab maintenance in patients with relapsed indolent non-Hodgkin lymphoma after prior rituximab.
    Leuk Lymphoma. 2021 Jan 15:1-8. doi: 10.1080/10428194.2020.1869957.
    PubMed     Abstract available

  77. CHERNG HJ, Westin J
    Why R-CHOP + X is not enough: lessons learned and next steps in the mission to improve frontline therapy for diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2021 Jan 6:1-17. doi: 10.1080/10428194.2020.1869228.
    PubMed     Abstract available

  78. HU S, Chen N, Lu K, Zhen C, et al
    The prognostic roles of hepatitis B virus antibody in diffuse large B-cell lymphoma patients.
    Leuk Lymphoma. 2021 Jan 5:1-15. doi: 10.1080/10428194.2020.1867726.
    PubMed     Abstract available

  79. POLPRASERT C, Takeuchi Y, Makishima H, Wudhikarn K, et al
    Frequent mutations in HLA and related genes in extranodal NK/T cell lymphomas.
    Leuk Lymphoma. 2021;62:95-103.
    PubMed     Abstract available

  80. VOORHEES TJ, Kannan KK, Galeotti J, Grover N, et al
    Identification of high-risk monomorphic post-transplant lymphoproliferative disorder following solid organ transplantation.
    Leuk Lymphoma. 2021;62:86-94.
    PubMed     Abstract available

    December 2020
  81. MIAN A, Wei W, Winter AM, Khouri J, et al
    Outcomes and factors impacting use of axicabtagene ciloleucel in patients with relapsed or refractory large B-cell lymphoma: results from an intention-to-treat analysis.
    Leuk Lymphoma. 2020 Dec 29:1-9. doi: 10.1080/10428194.2020.1864349.
    PubMed     Abstract available

  82. DABAJA BS, Milgrom SA, Wirth A
    Secondary central nervous system diffuse large cell lymphoma: an opportunity for radiation therapy to improve outcomes.
    Leuk Lymphoma. 2020 Dec 25:1-4. doi: 10.1080/10428194.2020.1864353.

  83. NORDMO C, Glehr G, Altenbuchinger M, Spang R, et al
    Identification of a miRNA based model to detect prognostic subgroups in patients with aggressive B-cell lymphoma.
    Leuk Lymphoma. 2020 Dec 22:1-15. doi: 10.1080/10428194.2020.1861268.
    PubMed     Abstract available

  84. SZAFER-GLUSMAN E, Liu J, Sinha A, Peale FV Jr, et al
    Evaluation of the effect of prospective biomarker testing on progression-free survival in diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2020 Dec 16:1-4. doi: 10.1080/10428194.2020.1849674.

  85. ILTAR U, Sozel H, Sozel YK, Atas U, et al
    Prognostic impact of the psoas muscle index, a parameter of sarcopenia, in patients with diffuse large B-cell lymphoma treated with rituximab-based chemoimmunotherapy.
    Leuk Lymphoma. 2020 Dec 10:1-9. doi: 10.1080/10428194.2020.1856833.
    PubMed     Abstract available

  86. BARRIENTOS JC, Hillmen P, Salles G, Sharman J, et al
    No increased bleeding events in patients with relapsed chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma treated with idelalisib.
    Leuk Lymphoma. 2020 Dec 10:1-9. doi: 10.1080/10428194.2020.1845339.
    PubMed     Abstract available

  87. TEXTE E, Lequesne J, Tilly H, Jardin F, et al
    SUVmax-based assessment of PET response shows a superior specificity to Deauville criteria for predicting recurrence in Hodgkin's lymphoma.
    Leuk Lymphoma. 2020 Dec 8:1-14. doi: 10.1080/10428194.2020.1855341.
    PubMed     Abstract available

  88. VELA-OJEDA J, Perez-Retiguin FDC, Olivas-Bejarano AC, Garcia-Ruiz Esparza MA, et al
    Clinical relevance of NKT cells and soluble MIC-A in Hodgkin lymphoma.
    Leuk Lymphoma. 2020 Dec 7:1-12. doi: 10.1080/10428194.2020.1852473.
    PubMed     Abstract available

  89. GEEL JA, Eyal KC, Hendricks MG, Myezo KH, et al
    Prognostic factors affecting survival in children and adolescents with HIV and Hodgkin lymphoma in South Africa.
    Leuk Lymphoma. 2020 Dec 7:1-14. doi: 10.1080/10428194.2020.1852472.
    PubMed     Abstract available

  90. POVEDA J, Cassidy DP, Zhou Y, Alderuccio JP, et al
    Expression of germinal center cell markers by extranodal marginal zone lymphomas of MALT type within colonized follicles, a diagnostic pitfall with follicular lymphoma.
    Leuk Lymphoma. 2020 Dec 7:1-7. doi: 10.1080/10428194.2020.1855347.
    PubMed     Abstract available

  91. FOX TA, Carpenter B, Taj M, Perisoglou M, et al
    Utility of 18F-FDG-PET/CT in lymphoblastic lymphoma.
    Leuk Lymphoma. 2020 Dec 4:1-6. doi: 10.1080/10428194.2020.1855346.

  92. MORIGI A, Casadei B, Argnani L, Stefoni V, et al
    Successful stem cell harvest and autologous transplantation in a patient with cold agglutinin syndrome and aggressive lymphoma.
    Leuk Lymphoma. 2020 Dec 4:1-3. doi: 10.1080/10428194.2020.1855342.

  93. DI ROCCO A, Cuneo A, Di Rocco A, Merli F, et al
    Relapsed/refractory diffuse large B-cell lymphoma patients. A multicenter retrospective analysis of eligibility criteria for car-T cell therapy.
    Leuk Lymphoma. 2020 Dec 4:1-11. doi: 10.1080/10428194.2020.1849676.
    PubMed     Abstract available

  94. BALLAS LK, Metzger ML, Milgrom SA, Advani R, et al
    Nodular lymphocyte predominant Hodgkin lymphoma: executive summary of the American radium society appropriate use criteria.
    Leuk Lymphoma. 2020 Dec 4:1-14. doi: 10.1080/10428194.2020.1852559.
    PubMed     Abstract available

  95. PARKS AL, Kambhampati S, Fakhri B, Andreadis C, et al
    Incidence, management and outcomes of arterial and venous thrombosis after chimeric antigen receptor modified T cells for B cell lymphoma and multiple myeloma.
    Leuk Lymphoma. 2020 Dec 1:1-6. doi: 10.1080/10428194.2020.1852474.

    November 2020
  96. RODRIGUEZ-LOPEZ JL, Patel AK, Balasubramani GK, Glaser SM, et al
    Treatment selection and survival outcomes in Early-Stage peripheral T-Cell lymphomas: does anaplastic lymphoma kinase mutation impact the benefit of consolidative radiotherapy?
    Leuk Lymphoma. 2020 Nov 30:1-11. doi: 10.1080/10428194.2020.1842398.
    PubMed     Abstract available

  97. VOCKOVA P, Molinsky J, Klanova M, Karban J, et al
    CD31/PECAM-1 impacts engraftment, growth and spread of mantle cell lymphoma cells and positively correlates with extramedullary involvement.
    Leuk Lymphoma. 2020 Nov 25:1-8. doi: 10.1080/10428194.2020.1849678.
    PubMed     Abstract available

  98. CHASE ML, Merryman R, Fisher DC, Jacobsen E, et al
    A prospective study of minimal residual disease in patients with diffuse large B-cell lymphoma using an Ig-NGS assay.
    Leuk Lymphoma. 2020 Nov 25:1-4. doi: 10.1080/10428194.2020.1830390.

  99. PAPADAKIS V, Efstathopoulou M, Angelopoulou MK, Tsourouflis G, et al
    Curative surgery in highly selected patients with heavily pretreated, relapsed/refractory classical Hodgkin lymphoma.
    Leuk Lymphoma. 2020 Nov 25:1-5. doi: 10.1080/10428194.2020.1842404.

  100. COX MC, Nusca SM, Di Landro F, Marsilli G, et al
    Exercise training (ET) in adult and elderly patients receiving anti-lymphoma treatments is feasible and may improve the provision of care.
    Leuk Lymphoma. 2020 Nov 24:1-11. doi: 10.1080/10428194.2020.1842396.
    PubMed     Abstract available

  101. MENG G, Wang Y, Wang J, Wang Z, et al
    The DEP regimen is superior to the HLH-1994 regimen as first-line therapy for lymphoma-associated haemophagocytic lymphohistiocytosis.
    Leuk Lymphoma. 2020 Nov 21:1-13. doi: 10.1080/10428194.2020.1849671.
    PubMed     Abstract available

  102. SCOTT AJ, Tokaz MC, Shango M, Devata S, et al
    Clinical application of next generation sequencing in lymphoma.
    Leuk Lymphoma. 2020 Nov 16:1-6. doi: 10.1080/10428194.2020.1846734.
    PubMed     Abstract available

  103. YAMASAKI S, Iida H, Yoshida I, Komeno T, et al
    Comparison of prognostic scores in transplant-ineligible patients with peripheral T-cell lymphoma not otherwise specified and angioimmunoblastic T-cell lymphoma: a retrospective study from the national hospital organization in Japan.
    Leuk Lymphoma. 2020 Nov 9:1-9. doi: 10.1080/10428194.2020.1845336.
    PubMed     Abstract available

  104. CHEN MT, Fu XH, Huang H, Wang Z, et al
    Combination of crizotinib and chemotherapy in patients with relapsed or refractory anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL).
    Leuk Lymphoma. 2020 Nov 6:1-10. doi: 10.1080/10428194.2020.1839658.
    PubMed     Abstract available

  105. PAN J, Ghimire S, Alpdogan SO, Chapman A, et al
    Phase I/II study of bendamustine in combination with ofatumumab, carboplatin, etoposide (BOCE) for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma.
    Leuk Lymphoma. 2020 Nov 4:1-8. doi: 10.1080/10428194.2020.1842400.
    PubMed     Abstract available

  106. HARKINS RA, Flowers CR
    How should clinicians interpret conflicting cost-effectiveness analyses for the treatment of lymphoma across nations and payer models?
    Leuk Lymphoma. 2020 Nov 4:1-4. doi: 10.1080/10428194.2020.1837798.

  107. COLEMAN M, Belada D, Casasnovas RO, Gressin R, et al
    Phase 2 study of parsaclisib (INCB050465), a highly selective, next-generation PI3Kdelta inhibitor, in relapsed or refractory diffuse large B-cell lymphoma (CITADEL-202).
    Leuk Lymphoma. 2020 Nov 3:1-9. doi: 10.1080/10428194.2020.1832660.
    PubMed     Abstract available

  108. MADSEN C, Plesner TL, Bentzen HH, Jorgensen J, et al
    Real world data on histological transformation in patients with follicular lymphoma: incidence, clinico-pathological risk factors and outcome in a nationwide Danish cohort.
    Leuk Lymphoma. 2020;61:2584-2594.
    PubMed     Abstract available

  109. LEWIS KL, Cheah CY
    Event free survival at 12 months (EFS12) in stage 1 DLBCL - a reassuring milestone?
    Leuk Lymphoma. 2020;61:2542-2543.

    October 2020
  110. MOERDLER S, Ewart M, Friedman DL, Kelly K, et al
    LAG-3 is expressed on a majority of tumor infiltrating lymphocytes in pediatric Hodgkin lymphoma.
    Leuk Lymphoma. 2020 Oct 28:1-8. doi: 10.1080/10428194.2020.1839651.
    PubMed     Abstract available

  111. BLANSKY D, Fazzari M, Mantzaris I, Rohan T, et al
    Racial and ethnic differences in diffuse large B-cell lymphoma survival among an underserved, urban population.
    Leuk Lymphoma. 2020 Oct 28:1-9. doi: 10.1080/10428194.2020.1839656.
    PubMed     Abstract available

  112. RODGERS TD, Williams AM, Baran A, Reagan PM, et al
    Toxicity patterns of novel PI3K combinations in patients with non-Hodgkin lymphoma.
    Leuk Lymphoma. 2020 Oct 25:1-8. doi: 10.1080/10428194.2020.1837796.
    PubMed     Abstract available

  113. HAMDI L, Creidy R, Boudjemaa S, Hendel-Chavez H, et al
    Frequent altered distribution of peripheral B-lymphocyte subsets in pediatric and adolescent patients with classical Hodgkin lymphoma.
    Leuk Lymphoma. 2020 Oct 23:1-8. doi: 10.1080/10428194.2020.1834090.
    PubMed     Abstract available

  114. YOUNES S, Natkunam Y
    FOXes at play in the lymphoma landscape.
    Leuk Lymphoma. 2020 Oct 16:1-3. doi: 10.1080/10428194.2020.1834099.

  115. PAN BH, Kong YL, Wang L, Zhu HY, et al
    The prognostic roles of hypogammaglobulinemia and hypocomplementemia in newly diagnosed diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2020 Oct 16:1-9. doi: 10.1080/10428194.2020.1832673.
    PubMed     Abstract available

  116. LEHRICH BM, Goshtasbi K, Abiri A, Yasaka TM, et al
    Treatment modalities and overall survival outcomes for sinonasal extranodal natural killer/T-cell lymphoma.
    Leuk Lymphoma. 2020 Oct 15:1-4. doi: 10.1080/10428194.2020.1834097.

  117. LIU W, Wu M, Xie Y, Zhang C, et al
    Autologous hematopoietic stem cell transplantation with inadequate stem cell dose in patients with non-Hodgkin lymphoma.
    Leuk Lymphoma. 2020 Oct 15:1-7. doi: 10.1080/10428194.2020.1834092.
    PubMed     Abstract available

  118. CUI L, Gao C, Wang CJ, Zhao XX, et al
    Combined analysis of IKZF1 deletions and CRLF2 expression on prognostic impact in pediatric B-cell precursor acute lymphoblastic leukemia.
    Leuk Lymphoma. 2020 Oct 15:1-9. doi: 10.1080/10428194.2020.1832668.
    PubMed     Abstract available

  119. POPHALI PA, Larson MC, Rosenthal AC, Robinson D, et al
    The association of health behaviors with quality of life in lymphoma survivors.
    Leuk Lymphoma. 2020 Oct 13:1-10. doi: 10.1080/10428194.2020.1830389.
    PubMed     Abstract available

  120. RUSSLER-GERMAIN DA, Watkins MP, Bartlett NL
    A forgotten friend: CCNU as palliative monotherapy in relapsed Hodgkin lymphoma.
    Leuk Lymphoma. 2020 Oct 8:1-3. doi: 10.1080/10428194.2020.1830391.

  121. BHURANI M, Admojo L, Van Der Weyden C, Twigger R, et al
    Pralatrexate in relapsed/refractory T-cell lymphoma: a retrospective multicenter study.
    Leuk Lymphoma. 2020 Oct 7:1-7. doi: 10.1080/10428194.2020.1827241.
    PubMed     Abstract available

  122. ALMASMOUM HA, Airhihen B, Seedhouse C, Winkler GS, et al
    Frequent loss of BTG1 activity and impaired interactions with the Caf1 subunit of the Ccr4-Not deadenylase in non-Hodgkin lymphoma.
    Leuk Lymphoma. 2020 Oct 6:1-10. doi: 10.1080/10428194.2020.1827243.
    PubMed     Abstract available

  123. HWANG SR, Higgins A, Castillo Almeida NE, LaPlant B, et al
    Effect of antibiotic use on outcomes in patients with Hodgkin lymphoma treated with immune checkpoint inhibitors.
    Leuk Lymphoma. 2020 Oct 6:1-5. doi: 10.1080/10428194.2020.1827250.

    September 2020
  124. SEGMAN Y, Ribakovsky E, Avigdor A, Goldhecht Y, et al
    Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience.
    Leuk Lymphoma. 2020 Sep 27:1-7. doi: 10.1080/10428194.2020.1824069.
    PubMed     Abstract available

  125. TATARCZUCH M, Paul E, Gilberston M, Gregory GP, et al
    Excellent outcomes in older patients with primary CNS lymphoma treated with R-MPV/cytarabine without whole brain radiotherapy or autologous stem cell transplantation therapy.
    Leuk Lymphoma. 2020 Sep 27:1-6. doi: 10.1080/10428194.2020.1821007.
    PubMed     Abstract available

  126. HABERMANN TM, Khurana A, Lentz R, Schmitz JJ, et al
    Analysis and impact of a multidisciplinary lymphoma virtual tumor board.
    Leuk Lymphoma. 2020 Sep 23:1-9. doi: 10.1080/10428194.2020.1817432.
    PubMed     Abstract available

  127. CHANG C, Chen YP, Medeiros LJ, Chen TY, et al
    Higher infiltration of intratumoral CD25+FOXP3+ lymphocytes correlates with a favorable prognosis in patients with diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2020 Sep 23:1-10. doi: 10.1080/10428194.2020.1817438.
    PubMed     Abstract available

  128. KAYA EA, Baughn LB, Pham T, Ketterling RP, et al
    Lymphoma-like double-hit genetic abnormalities (MYC/IGH and IGH/BCL2) in a case of non-secretory multiple myeloma.
    Leuk Lymphoma. 2020 Sep 21:1-4. doi: 10.1080/10428194.2020.1821012.

  129. MOZAS P, Rivero A, Rivas-Delgado A, Nadeu F, et al
    A low lymphocyte-to-monocyte ratio is an independent predictor of poorer survival and higher risk of histological transformation in follicular lymphoma.
    Leuk Lymphoma. 2020 Sep 19:1-8. doi: 10.1080/10428194.2020.1821010.
    PubMed     Abstract available

  130. WALBURN T, Grover NS, Shen CJ, Ranganathan R, et al
    Consolidative or palliative whole brain radiation for secondary CNS diffuse large B-Cell lymphoma.
    Leuk Lymphoma. 2020 Sep 16:1-8. doi: 10.1080/10428194.2020.1821014.
    PubMed     Abstract available

  131. SAMANIEGO F, McLaughlin P, Neelapu SS, Feng L, et al
    Initial report of a phase II study with R-FND followed by ibritumomab tiuxetan radioimmunotherapy and rituximab maintenance in patients with untreated high-risk follicular lymphoma.
    Leuk Lymphoma. 2020 Sep 14:1-10. doi: 10.1080/10428194.2020.1821005.
    PubMed     Abstract available

  132. JAN MRU, Saeed H, Abubakar M, Wali RM, et al
    Response rates, long term outcomes and toxicity profile of gemcitabine and vinorelbine based outpatient chemotherapy regimen in primary progressive and relapsed childhood Hodgkin lymphoma.
    Leuk Lymphoma. 2020 Sep 13:1-9. doi: 10.1080/10428194.2020.1817434.
    PubMed     Abstract available

  133. KIM M, Hwang HS, Son EM, Cho H, et al
    Clinicopathological and prognostic significance of BCL2, BCL6, MYC, and IRF4 copy number gains and translocations in follicular lymphoma: a study by FISH analysis.
    Leuk Lymphoma. 2020 Sep 13:1-9. doi: 10.1080/10428194.2020.1815017.
    PubMed     Abstract available

  134. ANTEL K, Louw VJ, Maartens G, Oosthuizen J, et al
    Diagnosing lymphoma in the shadow of an epidemic: lessons learned from the diagnostic challenges posed by the dual tuberculosis and HIV epidemics.
    Leuk Lymphoma. 2020 Sep 13:1-5. doi: 10.1080/10428194.2020.1815016.
    PubMed     Abstract available

  135. DI M, Panagiotou OA, Reagan JL, Niroula R, et al
    Adjuvant chemotherapy administration and survival outcomes of lymphoma survivors with common solid tumors: a population-based studydagger.
    Leuk Lymphoma. 2020 Sep 11:1-9. doi: 10.1080/10428194.2020.1817433.
    PubMed     Abstract available

  136. NAKAMURA F, Arai H, Tokita K, Furuichi S, et al
    PECAM is an effective and safe anthracycline-containing third-line regimen for patients with relapsed or refractory non-Hodgkin lymphoma.
    Leuk Lymphoma. 2020 Sep 11:1-4. doi: 10.1080/10428194.2020.1817442.

  137. GLOVER A, Fox CP, McMillan A, Beech A, et al
    A comparison of bendamustine-EAM versus BEAM conditioning for autogolous stem cell transplant in lymphoma.
    Leuk Lymphoma. 2020 Sep 8:1-3. doi: 10.1080/10428194.2020.1811863.

  138. STUBBINS RJ, Mabilangan C, Rojas-Vasquez M, Lai RL, et al
    Classic Hodgkin lymphoma post-transplant lymphoproliferative disorders (PTLD) are often preceded by discordant PTLD subtypes.
    Leuk Lymphoma. 2020 Sep 2:1-12. doi: 10.1080/10428194.2020.1808206.
    PubMed     Abstract available

    August 2020
  139. HARWOOD M, Hodges G, Tan X, Cheah CY, et al
    Characteristics and outcome of patients with relapsed/refractory Hodgkin lymphoma following front-line escalated BEACOPP-based chemotherapy: a report from the Australasian Lymphoma Alliance.
    Leuk Lymphoma. 2020 Aug 28:1-5. doi: 10.1080/10428194.2020.1811273.
    PubMed     Abstract available

  140. CHINEN Y, Tanba K, Takagi R, Uchiyama H, et al
    Second primary malignancy after rituximab-containing immunochemotherapy for diffuse large B cell lymphoma.
    Leuk Lymphoma. 2020 Aug 27:1-9. doi: 10.1080/10428194.2020.1811862.
    PubMed     Abstract available

  141. GHIONE P, Qi S, Imber BS, Seshan V, et al
    Modified SMILE (mSMILE) and intensity-modulated radiotherapy (IMRT) for extranodal NK-T lymphoma nasal type in a single-center population.
    Leuk Lymphoma. 2020 Aug 26:1-11. doi: 10.1080/10428194.2020.1811864.
    PubMed     Abstract available

  142. STRAUS D, Collins G, Walewski J, Zinzani PL, et al
    Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy.
    Leuk Lymphoma. 2020 Aug 25:1-8. doi: 10.1080/10428194.2020.1791846.
    PubMed     Abstract available

  143. XU-MONETTE ZY, Young KH
    Therapeutic vaccines for aggressive B-cell lymphoma.
    Leuk Lymphoma. 2020 Aug 25:1-14. doi: 10.1080/10428194.2020.1805113.
    PubMed     Abstract available

  144. PATEL KK, Isufi I, Kothari S, Foss F, et al
    Cost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2020 Aug 24:1-8. doi: 10.1080/10428194.2020.1808208.
    PubMed     Abstract available

  145. CHEN Y, Luo L, Zheng X, Fu H, et al
    Clinical characteristics and survival of extranodal natural killer/T-cell lymphoma: a single-center 12-year retrospective analysis.
    Leuk Lymphoma. 2020 Aug 21:1-13. doi: 10.1080/10428194.2020.1808207.
    PubMed     Abstract available

  146. KRITTIKARUX S, Wudhikarn K, Tangnuntachai N, Assanasen T, et al
    The influence of programmed cell death ligand 2 (PD-L2) expression on survival outcome and tumor microenvironment in diffuse large B cell lymphoma.
    Leuk Lymphoma. 2020 Aug 21:1-9. doi: 10.1080/10428194.2020.1808209.
    PubMed     Abstract available

  147. BAI B, Gao Y, Wang XX, He HX, et al
    Identifying high-risk patients with natural killer/T-cell lymphoma undergoing autologous stem cell transplantation.
    Leuk Lymphoma. 2020 Aug 20:1-8. doi: 10.1080/10428194.2020.1808203.
    PubMed     Abstract available

  148. WEI C, Zhang W, Zhou D
    Central nervous system involvement at diagnosis in extranodal natural killer/T-cell lymphoma: a single-center study.
    Leuk Lymphoma. 2020 Aug 12:1-3. doi: 10.1080/10428194.2020.1804561.

  149. FRASER GAM, Chanan-Khan A, Demirkan F, Santucci Silva R, et al
    Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Leuk Lymphoma. 2020 Aug 6:1-10. doi: 10.1080/10428194.2020.1795159.
    PubMed     Abstract available

  150. OBIORAH IE, Francischetti IMB, Wang HW, Ahn IE, et al
    Concurrent chronic lymphocytic leukemia/small lymphocytic lymphoma and hairy cell leukemia: clinical, pathologic and molecular features.
    Leuk Lymphoma. 2020 Aug 5:1-11. doi: 10.1080/10428194.2020.1797007.
    PubMed     Abstract available

  151. LOSSOS IS, Reis IM, Rosenblatt JD, Alderuccio JP, et al
    Long-term outcomes of frontline (90)Y-ibritumomab tiuxetan in marginal zone lymphoma.
    Leuk Lymphoma. 2020 Aug 5:1-5. doi: 10.1080/10428194.2020.1802449.

  152. SUNDARAM S, Jizzini M, Lamonica D, Attwood K, et al
    Utility of bone marrow aspirate and biopsy in staging of patients with T-cell lymphoma in the PET-Era - tissue remains the issue.
    Leuk Lymphoma. 2020 Aug 4:1-8. doi: 10.1080/10428194.2020.1798950.
    PubMed     Abstract available

    July 2020
  153. CHERIYALINKAL PARAMBIL B, Narula G, Dhamne C, Roy Moulik N, et al
    Assessment of tumor Epstein-Barr Virus status and its impact on outcomes in intermediate and high-risk childhood classic Hodgkin Lymphoma treated at a tertiary cancer center in India.
    Leuk Lymphoma. 2020 Jul 30:1-9. doi: 10.1080/10428194.2020.1800005.
    PubMed     Abstract available

  154. VAN DER WEYDEN C, Harrop S, Prince HM
    Pralatrexate and angioimmunoblastic T-cell lymphoma: time for a second look?
    Leuk Lymphoma. 2020 Jul 30:1-3. doi: 10.1080/10428194.2020.1795164.

  155. SARKOZY C, Scott DW
    Follicular lymphoma - a better understanding to transform outcomes?
    Leuk Lymphoma. 2020 Jul 30:1-3. doi: 10.1080/10428194.2020.1791857.

  156. GIFFORD G, Stevenson W, Best G
    Combination of the dual PIM/PI3-kinase inhibitor IBL-202 and venetoclax is effective in diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2020 Jul 29:1-12. doi: 10.1080/10428194.2020.1795156.
    PubMed     Abstract available

  157. SAWAS A, Ma H, Kuruvilla J, Lue JK, et al
    Prolonged progression free survival in a subset of responders to the combination of brentuximab vedotin and bendamustine in heavily treated patients with relapsed or refractory Hodgkin lymphoma: updated results from an international multi-center phase
    Leuk Lymphoma. 2020 Jul 28:1-4. doi: 10.1080/10428194.2020.1795161.

  158. MEYNARD L, Galtier J, Favre S, Debus L, et al
    Vinblastine for elderly and frail patients with Hodgkin lymphoma.
    Leuk Lymphoma. 2020 Jul 27:1-4. doi: 10.1080/10428194.2020.1797009.

  159. LU T, Gibiansky L, Li X, Li C, et al
    Exposure-safety and exposure-efficacy analyses of polatuzumab vedotin in patients with relapsed or refractory diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2020 Jul 24:1-10. doi: 10.1080/10428194.2020.1795154.
    PubMed     Abstract available

  160. ALBANO D, Mazzoletti A, Zilioli VR, Muzi C, et al
    Clinical and prognostic role of interim 18F-FDG PET/CT in elderly Hodgkin lymphoma: a dual-center experience.
    Leuk Lymphoma. 2020 Jul 24:1-8. doi: 10.1080/10428194.2020.1797012.
    PubMed     Abstract available

  161. ABE R, Mori T, Tanigawa T, Koda Y, et al
    Clinical characteristics and outcomes of duodenal-type follicular lymphoma.
    Leuk Lymphoma. 2020 Jul 22:1-3. doi: 10.1080/10428194.2020.1795162.

  162. WEI L, Wang L, Cong J, Yang L, et al
    Treatment outcomes and prognostic analysis of elderly patients with extranodal natural killer/T-cell lymphoma, nasal type: a retrospective analysis.
    Leuk Lymphoma. 2020 Jul 20:1-7. doi: 10.1080/10428194.2020.1791848.
    PubMed     Abstract available

  163. KHAN N, Feliciano J, Muller K, He M, et al
    Patient preferences for first-line treatment of classical Hodgkin lymphoma: a US survey and discrete choice experiment.
    Leuk Lymphoma. 2020 Jul 20:1-8. doi: 10.1080/10428194.2020.1783443.
    PubMed     Abstract available

  164. SOUMERAI JD, Ni A, Alperovich A, Batlevi C, et al
    Time from diagnosis to 2nd treatment is a promising surrogate for overall survival in patients with advanced stage follicular lymphoma.
    Leuk Lymphoma. 2020 Jul 15:1-8. doi: 10.1080/10428194.2020.1791850.
    PubMed     Abstract available

  165. DESAI SH, Al-Shbool G, Desale S, Veis J, et al
    Lymphoma survivors have an increased long-term risk of chronic kidney disease.
    Leuk Lymphoma. 2020 Jul 11:1-8. doi: 10.1080/10428194.2020.1786555.
    PubMed     Abstract available

  166. MARTINEZ C, Boumendil A, Romejko-Jarosinska J, Anagnostopoulos A, et al
    Second autologous stem cell transplantation for relapsed/refractory Hodgkin lymphoma after a previous autograft: a study of the lymphoma working party of the EBMT.
    Leuk Lymphoma. 2020 Jul 11:1-8. doi: 10.1080/10428194.2020.1789624.
    PubMed     Abstract available

  167. PARTANEN A, Turunen A, Valtola J, Pyorala M, et al
    Autologous stem cell transplantation in peripheral T-cell lymphoma: better mobilization of blood CD34(+) cells is associated with improved survival.
    Leuk Lymphoma. 2020 Jul 10:1-3. doi: 10.1080/10428194.2020.1789629.

  168. FURQAN F, Watson G, Samaniego F, Fayad LE, et al
    Ibrutinib-based therapy for the treatment of marginal zone lymphoma with central nervous system involvement.
    Leuk Lymphoma. 2020 Jul 10:1-5. doi: 10.1080/10428194.2020.1791849.

    Diffuse large B cell lymphoma: splenectomy as a cure for a spleen-limited disease.
    Leuk Lymphoma. 2020 Jul 9:1-4. doi: 10.1080/10428194.2020.1788018.

  170. ISUFI I, Seropian S, Gowda L, Wilson LD, et al
    Outcomes for allogeneic stem cell transplantation in refractory mycosis fungoides and primary cutaneous gamma Delta T cell lymphomas.
    Leuk Lymphoma. 2020 Jul 9:1-7. doi: 10.1080/10428194.2020.1790555.
    PubMed     Abstract available

  171. VIARDOT A, Hess G, Bargou RC, Morley NJ, et al
    Durability of complete response after blinatumomab therapy for relapsed/refractory diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2020 Jul 7:1-4. doi: 10.1080/10428194.2020.1783442.

  172. CHIN CK, Rodriguez MA, Qing Y, Feng L, et al
    Impact of maintenance rituximab in patients with de novo transformed indolent B cell lymphoma.
    Leuk Lymphoma. 2020 Jul 6:1-5. doi: 10.1080/10428194.2020.1789631.

  173. BARRETO JN, Thompson CA, Wieruszewski PM, Pawlenty AG, et al
    Incidence, clinical presentation, and outcomes of Pneumocystis pneumonia when utilizing Polymerase Chain Reaction-based diagnosis in patients with Hodgkin lymphoma.
    Leuk Lymphoma. 2020 Jul 5:1-8. doi: 10.1080/10428194.2020.1786561.
    PubMed     Abstract available

  174. NEEMAN Y, Perry C, Silverman B, Waintraub N, et al
    Rituximab is not associated with increased risk of second primary malignancies in Israeli patients with diffuse large B cell lymphoma treated with RCHOP regimen.
    Leuk Lymphoma. 2020 Jul 1:1-7. doi: 10.1080/10428194.2020.1779257.
    PubMed     Abstract available

  175. BUTEAU JP, Seymour JF, Hofman MS
    The evolving definition of bulky disease for lymphoma.
    Leuk Lymphoma. 2020;61:1525-1528.

  176. JURCZAK W, Dlugosz-Danecka M
    Rituximab biosimilars in clinical practice.
    Leuk Lymphoma. 2020;61:1523-1524.

    June 2020
  177. GUO R, Xu P, Xu H, Miao Y, et al
    The predictive value of pre-treatment (18)F-FDG PET/CT on treatment outcome in early-stage extranodal natural killer/T-cell lymphoma.
    Leuk Lymphoma. 2020 Jun 23:1-6. doi: 10.1080/10428194.2020.1783446.
    PubMed     Abstract available

  178. WUDHIKARN K, Bunworasate U, Julamanee J, Lekhakula A, et al
    Event-free survival at 12 months is a strong surrogate endpoint for stage 1 diffuse large B cell lymphoma: a report from Nation Wide Registry Thai Lymphoma Study Group.
    Leuk Lymphoma. 2020 Jun 23:1-8. doi: 10.1080/10428194.2020.1780586.
    PubMed     Abstract available

  179. MAHAJAN A, Brunson A, Keegan THM, Rosenberg A, et al
    High incidence of venous thromboembolism and major bleeding in patients with primary CNS lymphoma.
    Leuk Lymphoma. 2020 Jun 23:1-9. doi: 10.1080/10428194.2020.1780584.
    PubMed     Abstract available

  180. ALLEN PB, Switchenko J, Ayers A, Kim E, et al
    Risk of bacteremia in patients with cutaneous T-cell lymphoma (CTCL).
    Leuk Lymphoma. 2020 Jun 19:1-7. doi: 10.1080/10428194.2020.1779259.
    PubMed     Abstract available

  181. COYLE L, Morley NJ, Rambaldi A, Mason KD, et al
    Open-Label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
    Leuk Lymphoma. 2020 Jun 16:1-10. doi: 10.1080/10428194.2020.1759055.
    PubMed     Abstract available

  182. EDNERSSON SB, Stern M, Fagman H, Nilsson-Ehle H, et al
    TBLR1 and CREBBP as potential novel prognostic immunohistochemical biomarkers in diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2020 Jun 16:1-10. doi: 10.1080/10428194.2020.1775216.
    PubMed     Abstract available

  183. LU JP, Wang FX, Wen SP, Liu X, et al
    Haploidentical hematopoietic stem cell transplantation with 'Beijing protocol' in the treatment of T-lymphoblastic lymphoma.
    Leuk Lymphoma. 2020 Jun 16:1-4. doi: 10.1080/10428194.2020.1775205.

  184. ZHU J, Yeoh EM, Maeda Y, Tobinai K, et al
    Efficacy and safety of single-agent pralatrexate for treatment of angioimmunoblastic T-cell lymphoma after failure of first line therapy: a pooled analysis.
    Leuk Lymphoma. 2020 Jun 14:1-8. doi: 10.1080/10428194.2020.1765232.
    PubMed     Abstract available

  185. MATSUDA K, Taisuke J, Miyauchi M, Toyama K, et al
    Primary prophylaxis with pegfilgrastim in patients with newly-diagnosed diffuse large B-cell lymphoma: propensity score and instrumental variable analyses.
    Leuk Lymphoma. 2020 Jun 12:1-7. doi: 10.1080/10428194.2020.1775207.
    PubMed     Abstract available

  186. AGRUSA JE, Kothari VD, Brown AL, Masand PM, et al
    Early evidence of pulmonary dysfunction in survivors of childhood Hodgkin lymphoma.
    Leuk Lymphoma. 2020 Jun 10:1-9. doi: 10.1080/10428194.2020.1772478.
    PubMed     Abstract available

  187. LIU J, Stewart D, Fontaine A, Peters A, et al
    Characteristics and outcomes of patients with relapsed follicular lymphoma following retreatment with second-line rituximab-containing chemotherapy.
    Leuk Lymphoma. 2020 Jun 10:1-5. doi: 10.1080/10428194.2020.1772472.

  188. WANG L, Chen XQ, Xia ZJ
    New tricks for old drugs: combination of rituximab and two nanoparticle-delivered chemotherapy drugs, albumin-bound paclitaxel and pegylated liposomal doxorubicin, in the treatment of relapsed/refractory diffuse large B cell lymphoma.
    Leuk Lymphoma. 2020 Jun 6:1-5. doi: 10.1080/10428194.2020.1775206.

  189. TANG C, Espin-Garcia O, Prica A, Kurkreti V, et al
    Efficacy and safety of stem cell mobilization following gemcitabine, dexamethasone, cisplatin (GDP) salvage chemotherapy in patients with relapsed or refractory lymphoma.
    Leuk Lymphoma. 2020 Jun 1:1-8. doi: 10.1080/10428194.2020.1762882.
    PubMed     Abstract available

  190. TADMOR T, Greenfeld S
    Incidence and diagnosis of Richter transformation: transition from the era of chemoimmunotherapy to novel targeted agents.
    Leuk Lymphoma. 2020;61:1272-1274.

  191. STRATI P, Ahmed MA, Nastoupil LJ, Feng L, et al
    Pretreatment SUVmax may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FL.
    Leuk Lymphoma. 2020;61:1380-1387.
    PubMed     Abstract available

    May 2020
  192. HAYASHIDA M, Maekawa F, Chagi Y, Iioka F, et al
    Combination of multicolor flow cytometry for circulating lymphoma cells and tests for the RHOA(G17V) and IDH2(R172) hot-spot mutations in plasma cell-free DNA as liquid biopsy for the diagnosis of angioimmunoblastic T-cell lymphoma.
    Leuk Lymphoma. 2020 May 30:1-10. doi: 10.1080/10428194.2020.1768382.
    PubMed     Abstract available

  193. WEIL CR, Qian Y, Von Eyben R, Daadi SE, et al
    Long-term outcomes of patients with unfavorable stage I-II classic Hodgkin lymphoma treated with Stanford V chemotherapy and limited field irradiation.
    Leuk Lymphoma. 2020 May 30:1-7. doi: 10.1080/10428194.2020.1768385.
    PubMed     Abstract available

  194. HA CS, LeBlanc M, Schoder H, Pinnix CC, et al
    Potential impact of consolidation radiation therapy for advanced Hodgkin lymphoma: a secondary analysis of SWOG S0816.
    Leuk Lymphoma. 2020 May 26:1-6. doi: 10.1080/10428194.2020.1768388.
    PubMed     Abstract available

  195. ASKLID A, Eketorp Sylvan S, Mattsson A, Winqvist M, et al
    A real-world study of first-line therapy in 280 consecutive Swedish patients >/=80 years with newly diagnosed diffuse large B-cell lymphoma: very elderly (>/=85 years) do well on curative intended therapy.
    Leuk Lymphoma. 2020 May 25:1-9. doi: 10.1080/10428194.2020.1765233.
    PubMed     Abstract available

  196. AGUILAR C, Laberiano C, Beltran B, Diaz C, et al
    Clinicopathologic characteristics and survival of patients with primary effusion lymphoma.
    Leuk Lymphoma. 2020 May 25:1-10. doi: 10.1080/10428194.2020.1762881.
    PubMed     Abstract available

  197. YANG R, Huo Z, Duan Y, Tong W, et al
    SOX11 inhibits tumor proliferation and promotes cell adhesion mediated-drug resistance via a CD43 dependent manner in mantle cell lymphoma.
    Leuk Lymphoma. 2020 May 23:1-14. doi: 10.1080/10428194.2020.1762877.
    PubMed     Abstract available

  198. KNEZ V, Bao L, Carstens B, Liang X, et al
    Analysis of clinicopathological and cytogenetic differences between B-lymphoblastic lymphoma and B-lymphoblastic leukemia in childhood.
    Leuk Lymphoma. 2020 May 19:1-7. doi: 10.1080/10428194.2020.1761970.
    PubMed     Abstract available

  199. PICKARD L, Palladino G, Okosun J
    Follicular lymphoma genomics.
    Leuk Lymphoma. 2020 May 19:1-11. doi: 10.1080/10428194.2020.1762883.
    PubMed     Abstract available

  200. MARCHESI F, Capria S, Pedata M, Terrenato I, et al
    BEAM conditioning regimen ensures better progression-free survival compared with TEAM but not with FEAM in lymphoma patients undergoing autologous stem cell transplant.
    Leuk Lymphoma. 2020 May 18:1-4. doi: 10.1080/10428194.2020.1765238.

  201. LANAMTIENG T, Teawtrakul N, Ungarreevittaya P
    Prevalence and clinical characteristics of EBV-positive diffuse large B-cell lymphoma in adult patients: a single center study in Thailand.
    Leuk Lymphoma. 2020 May 14:1-3. doi: 10.1080/10428194.2020.1765240.

  202. GAO C, Harrop S, Van Der Weyden C, McCormack C, et al
    Primary cutaneous anaplastic large cell lymphoma and evolving clinical practice: 26 years of skin lesions with locoregional progression to systemic disease.
    Leuk Lymphoma. 2020 May 12:1-3. doi: 10.1080/10428194.2020.1761972.

  203. FUSEYA H, Yoshida M, Oyama R, Tatsumi N, et al
    Mantle cell lymphoma with dot-like nuclear staining for cyclin D1.
    Leuk Lymphoma. 2020 May 12:1-4. doi: 10.1080/10428194.2020.1759050.

  204. NOZAKI K, Sugahara H, Ueda S, Ishikawa J, et al
    Pretreatment serum soluble interleukin-2 receptor level predicts survival in patients with newly diagnosed follicular lymphoma.
    Leuk Lymphoma. 2020 May 4:1-9. doi: 10.1080/10428194.2020.1759054.
    PubMed     Abstract available

  205. GILE J, Ruan G, Abeykoon J, McMahon MM, et al
    Hypomagnesemia is associated with an increased risk of early clinical failure in patients with Burkitt lymphoma.
    Leuk Lymphoma. 2020 May 2:1-3. doi: 10.1080/10428194.2020.1759056.

    The justification of vincristine dose capping: tradition, tradition...tradition!
    Leuk Lymphoma. 2020;61:1007-1009.

    April 2020
  207. KIM YE, Kim H, Shin J, Min SY, et al
    Stage IV natural killer/T-cell lymphoma with chronic active Epstein-Barr virus, treated with pembrolizumab and TCRalphabeta-depleted haploidentical hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2020 Apr 30:1-4. doi: 10.1080/10428194.2020.1757666.

  208. MERLI M, Defrancesco I, Visco C, Besson C, et al
    Direct-acting antivirals in relapsed or refractory hepatitis C virus-associated diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2020 Apr 28:1-7. doi: 10.1080/10428194.2020.1755859.
    PubMed     Abstract available

  209. RUAN J, Yamshon S, Besien KV, Martin P, et al
    An update on options of therapy for aggressive mantle cell lymphoma.
    Leuk Lymphoma. 2020 Apr 26:1-14. doi: 10.1080/10428194.2020.1755860.
    PubMed     Abstract available

  210. SAWAS A, Ma H, Shustov A, Hsu P, et al
    Characterizing the belinostat response in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma.
    Leuk Lymphoma. 2020 Apr 26:1-5. doi: 10.1080/10428194.2020.1753044.

  211. TERAO T, Narita K, Tsushima T, Miura D, et al
    Mantle cell lymphoma turned SOX11 negative after ibrutinib: a report of two cases.
    Leuk Lymphoma. 2020 Apr 23:1-3. doi: 10.1080/10428194.2020.1742904.

  212. PENG C, Li X, Huang H, Liu T, et al
    A prospective, crossover randomized trial of the optimal timing for leucovorin rescue after high-dose methotrexate management in adult non-Hodgkin's lymphoma patients.
    Leuk Lymphoma. 2020 Apr 22:1-8. doi: 10.1080/10428194.2020.1747061.
    PubMed     Abstract available

  213. LEE K, Ha JY, Jung AR, Lee YS, et al
    The clinical outcomes of rituximab biosimilar CT-P10 (Truxima((R))) with CHOP as first-line treatment for patients with diffuse large B-cell lymphoma: real-world experience.
    Leuk Lymphoma. 2020 Apr 15:1-9. doi: 10.1080/10428194.2020.1742906.
    PubMed     Abstract available

  214. TKACZ J, Garcia J, Gitlin M, McMorrow D, et al
    The economic burden to payers of patients with diffuse large B-cell lymphoma during the treatment period by line of therapy.
    Leuk Lymphoma. 2020 Apr 9:1-9. doi: 10.1080/10428194.2020.1734592.
    PubMed     Abstract available

  215. ZAYAC AS, Olszewski AJ
    Burkitt lymphoma: bridging the gap between advances in molecular biology and therapy.
    Leuk Lymphoma. 2020 Apr 7:1-13. doi: 10.1080/10428194.2020.1747068.
    PubMed     Abstract available

  216. GIFFORD GK, Gifford AJ, Chen Q, Shen Y, et al
    Fatty acid synthase and adenosine monophosphate-activated protein kinase regulate cell survival and drug sensitivity in diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2020 Apr 4:1-13. doi: 10.1080/10428194.2020.1742899.
    PubMed     Abstract available

    March 2020
  217. LIN RJ, Michaud L, Lobaugh SM, Nakajima R, et al
    The geriatric syndrome of sarcopenia impacts allogeneic hematopoietic cell transplantation outcomes in older lymphoma patients.
    Leuk Lymphoma. 2020 Mar 31:1-9. doi: 10.1080/10428194.2020.1742909.
    PubMed     Abstract available

  218. RODRIGUEZ-LOBATO LG, Martinez-Roca A, Moreno DF, Gutierrez-Garcia G, et al
    Impact of intensifying primary antibiotic prophylaxis in at-home autologous stem cell transplantation program for lymphoma patients.
    Leuk Lymphoma. 2020 Mar 25:1-10. doi: 10.1080/10428194.2020.1742901.
    PubMed     Abstract available

  219. GRABER JJ, Plato B, Mawad R, Moore DJ, et al
    Pembrolizumab immunotherapy for relapsed CNS Lymphoma.
    Leuk Lymphoma. 2020 Mar 23:1-3. doi: 10.1080/10428194.2020.1742903.

  220. MEACHAM PJ, Williams AM, Strawderman M, Baran AM, et al
    Additional B-cell malignancies in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL).
    Leuk Lymphoma. 2020 Mar 16:1-9. doi: 10.1080/10428194.2020.1737690.
    PubMed     Abstract available

  221. RIER HN, Kharagjitsing H, van Rosmalen J, van Vugt J, et al
    Prognostic impact of low muscle mass and low muscle density in patients with diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2020 Mar 13:1-8. doi: 10.1080/10428194.2020.1737686.
    PubMed     Abstract available

  222. BENTOLILA G, Pavlovsky A
    Relapse or refractory Hodgkin lymphoma: determining risk of relapse or progression after autologous stem-cell transplantation.
    Leuk Lymphoma. 2020 Mar 9:1-7. doi: 10.1080/10428194.2020.1732959.
    PubMed     Abstract available

    February 2020
  223. KIM DW, Lee G, Lee H, Mahal AR, et al
    Response to hyperfractionated accelerated radiotherapy in chemotherapy-refractory non-Hodgkin lymphoma.
    Leuk Lymphoma. 2020 Feb 26:1-7. doi: 10.1080/10428194.2020.1719096.
    PubMed     Abstract available

  224. ALLEN PB, Ayers A, Behera M, Evens AM, et al
    A systematic review of therapeutic regimens for older patients with newly diagnosed Hodgkin lymphoma.
    Leuk Lymphoma. 2020 Feb 26:1-10. doi: 10.1080/10428194.2020.1731497.
    PubMed     Abstract available

  225. DELABY G, Hubaut MA, Morschhauser F, Besson A, et al
    Prognostic value of the metabolic bulk volume in patients with diffuse large B-cell lymphoma on baseline (18)F-FDG PET-CT.
    Leuk Lymphoma. 2020 Feb 26:1-8. doi: 10.1080/10428194.2020.1728750.
    PubMed     Abstract available

  226. KORT J, Chidiac A, El Sayed R, Massoud R, et al
    Safety and efficacy of four cycles of Brentuximab Vedotin as consolidation after autologous peripheral stem cell transplantation in relapsed/refractory Hodgkin lymphoma.
    Leuk Lymphoma. 2020 Feb 22:1-4. doi: 10.1080/10428194.2020.1728755.
    PubMed     Abstract available

  227. SHENG D, Li T, Wang WG, Li MJ, et al
    Diffuse large B-cell lymphoma with low (18)F-fluorodeoxyglucose avidity features silent B-cell receptor signaling.
    Leuk Lymphoma. 2020 Feb 22:1-8. doi: 10.1080/10428194.2020.1713317.
    PubMed     Abstract available

  228. EROL-YILDIZ R, Kizilay T, Tuzun E, Misirli H, et al
    Nivolumab-induced autoantibody negative limbic encephalitis in a patient with Hodgkin lymphoma.
    Leuk Lymphoma. 2020 Feb 12:1-3. doi: 10.1080/10428194.2020.1725508.

  229. SHAIKH MP, Alite F, Pugliese N, Picardi M, et al
    Consolidation radiotherapy following positron emission tomography complete response in early-stage Hodgkin lymphoma: a meta-analysis.
    Leuk Lymphoma. 2020 Feb 12:1-8. doi: 10.1080/10428194.2020.1725506.
    PubMed     Abstract available

  230. BAECH J, Hansen SM, Jakobsen LH, Ovlisen AK, et al
    Increased risk of osteoporosis following commonly used first-line treatments for lymphoma: a Danish Nationwide Cohort Study.
    Leuk Lymphoma. 2020 Feb 11:1-10. doi: 10.1080/10428194.2020.1723015.
    PubMed     Abstract available

  231. NARAZAKI T, Shiratsuchi M, Matsushima T, Tsuda M, et al
    Clinico-pathological characteristics of primary adrenal lymphomas - potential efficacy of autologous stem cell transplantation.
    Leuk Lymphoma. 2020 Feb 10:1-3. doi: 10.1080/10428194.2020.1725507.

  232. IMBER BS, Chau K, Goldberg E, Joffe E, et al
    Grade 3A follicular lymphoma can be effectively controlled with very low-dose radiation therapy.
    Leuk Lymphoma. 2020 Feb 9:1-4. doi: 10.1080/10428194.2020.1716222.

  233. SCHMITZ C, Rekowski J, Reinke S, Muller SP, et al
    Metabolic tumor volume, cancer cell fraction, and prognosis - the case of T-cell/histiocyte-rich large B-cell lymphoma.
    Leuk Lymphoma. 2020 Feb 5:1-8. doi: 10.1080/10428194.2020.1713319.
    PubMed     Abstract available

  234. NIJLAND M, Kluin-Nelemans HC
    Late relapses in diffuse large B-cell lymphoma: where to move next?
    Leuk Lymphoma. 2020 Feb 4:1-2. doi: 10.1080/10428194.2020.1716224.

    January 2020
  235. CASTILLO JJ, Itchaki G, Gustine JN, Meid K, et al
    A matched case-control study comparing features, treatment and outcomes between patients with non-IgM lymphoplasmacytic lymphoma and Waldenstrom macroglobulinemia.
    Leuk Lymphoma. 2020 Jan 29:1-7. doi: 10.1080/10428194.2020.1719100.
    PubMed     Abstract available

  236. ICHIKAWA S, Fukuhara N, Saito K, Yokoyama H, et al
    Epstein-Barr virus-positive diffuse large B-cell lymphoma after sustained remission of T-cell prolymphocytic leukemia with alemtuzumab.
    Leuk Lymphoma. 2020 Jan 21:1-4. doi: 10.1080/10428194.2020.1713322.

  237. RYLAND GL, Fox LC, Wootton V, Thompson ER, et al
    Severe chemotherapy toxicity in a 10-year-old with T-acute lymphoblastic lymphoma harboring biallelic FANCM variants.
    Leuk Lymphoma. 2020 Jan 16:1-3. doi: 10.1080/10428194.2019.1711075.

  238. CHEN L, Tyryshkin K, Moore A, Scott DW, et al
    Objective quantification of BCL2 protein by multiplex immunofluorescence in routine biopsy samples of diffuse large B-cell lymphoma demonstrates associations with survival and BCL2 gene alterations.
    Leuk Lymphoma. 2020 Jan 16:1-11. doi: 10.1080/10428194.2020.1713318.
    PubMed     Abstract available

  239. GILLESSEN S, Kobe C, Engert A, von Tresckow B, et al
    PET positivity - the agony of choice: response assessment and interpretation of increased FDG uptake of residual mediastinal tissue after frontline therapy in Hodgkin lymphoma.
    Leuk Lymphoma. 2020 Jan 16:1-4. doi: 10.1080/10428194.2019.1711076.

  240. BECA JM, Raza K, Mow E, Keech J, et al
    Cost-effectiveness analysis of rituximab with methotrexate, cytarabine and thiotepa for the treatment of patients with primary central nervous system lymphoma.
    Leuk Lymphoma. 2020 Jan 13:1-11. doi: 10.1080/10428194.2020.1711902.
    PubMed     Abstract available

  241. PARIKH SA, Meacham PJ, Zent CS, Evans AG, et al
    Multiple B cell malignancies in patients with chronic lymphocytic leukemia: epidemiology, pathology, and clinical implications.
    Leuk Lymphoma. 2020 Jan 11:1-15. doi: 10.1080/10428194.2019.1709830.
    PubMed     Abstract available

  242. KHURANA A, Armand P, Ansell SM
    Checkpoint inhibition therapy as possible frontline therapy for Hodgkin lymphoma.
    Leuk Lymphoma. 2020 Jan 8:1-12. doi: 10.1080/10428194.2019.1709832.
    PubMed     Abstract available

  243. KANG J, Chae H, Hong JY, Yoon DH, et al
    Distinct clinical characteristics at diagnosis in patients with late relapses compared with early relapses of diffuse large B-cell lymphoma treated with R-CHOP.
    Leuk Lymphoma. 2020 Jan 6:1-7. doi: 10.1080/10428194.2019.1709831.
    PubMed     Abstract available

  244. ZINZANI PL, Chen R, Armand P, Johnson NA, et al
    Pembrolizumab monotherapy in patients with primary refractory classical hodgkin lymphoma who relapsed after salvage autologous stem cell transplantation and/or brentuximab vedotin therapy: KEYNOTE-087 subgroup analysis.
    Leuk Lymphoma. 2020 Jan 6:1-5. doi: 10.1080/10428194.2019.1702178.

  245. IVANOV V, Farnault L, Mercier C, Colavolpe C, et al
    Different sensitivity of CD19-positive bone marrow and lymph node lymphoblasts may cause resistance to blinatumomab in relapsed B-cell acute lymphoblastic leukemia/lymphoma.
    Leuk Lymphoma. 2020 Jan 3:1-4. doi: 10.1080/10428194.2019.1706737.

    December 2019
  246. MAIOLO E, Alma E, Napodano C, Gulli F, et al
    The prognostic impact of monoclonal immune globulin and free light chain secretion in diffuse large B cell lymphoma (DLBCL).
    Leuk Lymphoma. 2019 Dec 31:1-7. doi: 10.1080/10428194.2019.1706731.
    PubMed     Abstract available

  247. TAKAHASHI T, Ichikawa S, Ichinohasama R, Harigae H, et al
    BCR-ABL1 positive lymphoblastic lymphoma - should it be treated like a B-lymphoblastic leukemia with t(9;22);BCR-ABL1?
    Leuk Lymphoma. 2019 Dec 26:1-3. doi: 10.1080/10428194.2019.1706736.

  248. HSU YT, Wang YC, Chen RY, Hung LY, et al
    Angioimmunoblastic T-cell lymphoma in Taiwan reveals worse progression-free survival for RHOA G17V mutated subtype.
    Leuk Lymphoma. 2019 Dec 23:1-11. doi: 10.1080/10428194.2019.1702179.
    PubMed     Abstract available

  249. LIPSCOMB J, Switchenko JM, Flowers CR, Gillespie TW, et al
    Biologic, clinical, and sociodemographic predictors of multi-agent systemic therapy for non-Hodgkin lymphoma in people living with HIV: a population-based investigation in the state of Georgia.
    Leuk Lymphoma. 2019 Dec 18:1-9. doi: 10.1080/10428194.2019.1702176.
    PubMed     Abstract available

  250. JALALI S, Ansell SM
    The potential role of glycogen metabolism in diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2019 Dec 17:1-9. doi: 10.1080/10428194.2019.1702185.
    PubMed     Abstract available

  251. KIM YD, Kim TW, Ryu HJ, Lee YH, et al
    A diffuse large B cell lymphoma with clinical, imaging, and serologic characteristics of neuromyelitis optica spectrum disorder.
    Leuk Lymphoma. 2019 Dec 13:1-3. doi: 10.1080/10428194.2019.1699079.

  252. ZHAO Y, Shi Y, Shen H, Zhou, et al
    The prognostic value of platelet-lymphocyte ratio and neutrophil-lymphocyte ratio in the treatment response and survival of patients with peripheral T-cell lymphoma.
    Leuk Lymphoma. 2019 Dec 6:1-8. doi: 10.1080/10428194.2019.1700244.
    PubMed     Abstract available

  253. ZHANG Y, Chen S, Lin J, Wang Y, et al
    The option of treatment and outcomes for patients with AIDS-related diffuse large B-cell lymphoma from a resource-limited setting in China.
    Leuk Lymphoma. 2019 Dec 4:1-4. doi: 10.1080/10428194.2019.1697877.

    November 2019
  254. VIJAYASEKHARAN K, Prasad M, Pradhan ND, Phillip D, et al
    Favorable outcomes and reduced toxicity with a novel vinblastine-based non-high dose methotrexate (HDMTX) regimen (modified MCP-842) in pediatric anaplastic large cell lymphoma (ALCL): experience from India.
    Leuk Lymphoma. 2019 Nov 27:1-7. doi: 10.1080/10428194.2019.1695054.
    PubMed     Abstract available

  255. WANG M, Fang X, Wang X
    Emerging role of histone deacetylase inhibitors in the treatment of diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2019 Nov 26:1-13. doi: 10.1080/10428194.2019.1691194.
    PubMed     Abstract available

  256. RAFELSON W, Olszewski A
    What a headache! Double-hit lymphoma with CNS recurrence - Role of chimeric antigen receptor (CAR) T-cell therapy().
    Leuk Lymphoma. 2019 Nov 25:1-6. doi: 10.1080/10428194.2019.1695052.

  257. GUAN W, Jing Y, Dou L, Wang M, et al
    Chidamide in combination with chemotherapy in refractory and relapsed T lymphoblastic lymphoma/leukemia.
    Leuk Lymphoma. 2019 Nov 22:1-7. doi: 10.1080/10428194.2019.1691195.
    PubMed     Abstract available

  258. FLUMANN R, Nieper P, Reinhardt HC, Knittel G, et al
    New murine models of aggressive lymphoma.
    Leuk Lymphoma. 2019 Nov 22:1-11. doi: 10.1080/10428194.2019.1691200.
    PubMed     Abstract available

  259. CAHILL KE, Leukam MJ, Riedell PA
    Refining patient selection for CAR T-cell therapy in aggressive large B-cell lymphoma.
    Leuk Lymphoma. 2019 Nov 21:1-9. doi: 10.1080/10428194.2019.1691201.
    PubMed     Abstract available

  260. RODIN D, Ng A, Wirth A
    Ultra-low dose radiotherapy for salivary MALT lymphoma: lessons from small numbers.
    Leuk Lymphoma. 2019 Nov 21:1-3. doi: 10.1080/10428194.2019.1689395.

  261. TANNOURY J, Amiot A, Lemonnier F, Dupuis J, et al
    Colonic mucosa-associated lymphoid tissue lymphoma: a case series.
    Leuk Lymphoma. 2019 Nov 6:1-6. doi: 10.1080/10428194.2019.1686501.
    PubMed     Abstract available

  262. SALAS MQ, Mercadal S, Domingo Domenech E, Oliveira AC, et al
    Validation of the NCCN-IPI and the GELTAMO-IPI for diffuse large B-Cell lymphoma treated with R-CHOP in a large cohort of patients from a single institution.
    Leuk Lymphoma. 2019 Nov 5:1-7. doi: 10.1080/10428194.2019.1683733.
    PubMed     Abstract available

    October 2019
  263. KHULLAR K, Rivera-Nunez Z, Jhawar SR, Drachtman R, et al
    Pediatric hodgkin lymphoma: disparities in survival by race.
    Leuk Lymphoma. 2019 Oct 23:1-11. doi: 10.1080/10428194.2019.1680841.
    PubMed     Abstract available

  264. BAPTISTA MJ, Sole F, Polliack A, Matutes E, et al
    Report of the International Splenic Lymphoma Study Group meeting held in 2019 in Barcelona, Spain.
    Leuk Lymphoma. 2019 Oct 15:1-3. doi: 10.1080/10428194.2019.1675878.

  265. KUMAR P, Uppal M, Xiao W, Dogan A, et al
    Clonally-Related CD5+ CLL/SLL and CD10+ high grade B-cell lymphoma suggests common neoplastic progenitor with branched disease evolution, with therapeutic implications.
    Leuk Lymphoma. 2019 Oct 15:1-5. doi: 10.1080/10428194.2019.1675876.

  266. ZHUANG WH, Wang YP
    Analysis of the immunity effects after enhanced hepatitis B vaccination on patients with lymphoma.
    Leuk Lymphoma. 2019 Oct 15:1-7. doi: 10.1080/10428194.2019.1672053.
    PubMed     Abstract available

  267. HERBER M, Mertz P, Dieudonne Y, Guffroy B, et al
    Primary immunodeficiencies and lymphoma: a systematic review of literature.
    Leuk Lymphoma. 2019 Oct 3:1-11. doi: 10.1080/10428194.2019.1672056.
    PubMed     Abstract available

  268. BATOROV EV, Pronkina NV, Tikhonova MA, Kryuchkova IV, et al
    Increased circulating CD3(+) T cells are associated with early relapse following autologous hematopoietic stem cell transplantation in patients with classical Hodgkin lymphoma.
    Leuk Lymphoma. 2019;60:2488-2497.
    PubMed     Abstract available

    September 2019
  269. MYLES N, Giri P, Chim I, Kodituwakku A, et al
    The utility of CD200 expression and modified Matutes score in the diagnostic differentiation of mantle cell lymphoma and chronic lymphocytic leukemia using flow cytometry.
    Leuk Lymphoma. 2019 Sep 27:1-3. doi: 10.1080/10428194.2019.1663420.

  270. NOVO M, Nowakowski GS, Habermann TM, Witzig TE, et al
    Persistent mediastinal FDG uptake on PET-CT after frontline therapy for Hodgkin lymphoma: biopsy, treat or observe?
    Leuk Lymphoma. 2019 Sep 26:1-10. doi: 10.1080/10428194.2019.1663422.
    PubMed     Abstract available

    Beware of the neutrophil/lymphocyte ratio in diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2019 Sep 26:1-2. doi: 10.1080/10428194.2019.1668940.

  272. GHAFOOR T
    Prognostic factors in pediatric Hodgkin lymphoma: experience from a developing country.
    Leuk Lymphoma. 2019 Sep 19:1-7. doi: 10.1080/10428194.2019.1665666.
    PubMed     Abstract available

  273. HU B, Nastoupil LJ, Loghavi S, Westin JR, et al
    De novo CD5+ diffuse large B-cell lymphoma, NOS: clinical characteristics and outcomes in rituximab era.
    Leuk Lymphoma. 2019 Sep 18:1-9. doi: 10.1080/10428194.2019.1663418.
    PubMed     Abstract available

  274. NAKAYAMA S, Morita Y, Espinoza JL, Rai S, et al
    Multiple cytokine-producing B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classic Hodgkin lymphoma with autoimmune hemolytic anemia.
    Leuk Lymphoma. 2019 Sep 18:1-3. doi: 10.1080/10428194.2019.1665665.

  275. TAPARRA K, Liu H, Polley MY, Ristow K, et al
    Bleomycin use in the treatment of Hodgkin lymphoma (HL): toxicity and outcomes in the modern era.
    Leuk Lymphoma. 2019 Sep 13:1-11. doi: 10.1080/10428194.2019.1663419.
    PubMed     Abstract available

  276. WEI L, Wang J, Ye J, Yang L, et al
    Long-term outcomes of patients treated with an EPOCHL regimen as first-line chemotherapy for newly diagnosed extranodal natural killer/T-cell lymphoma: a retrospective single-center study.
    Leuk Lymphoma. 2019 Sep 13:1-7. doi: 10.1080/10428194.2019.1663421.
    PubMed     Abstract available

  277. JOSHI M, Taper J, Forsyth C, Rowlings P, et al
    Outpatient rituximab, ifosfamide, etoposide (R-IE) in patients older than 60 years with relapsed or refractory diffuse large B-cell lymphoma who are not candidates for stem cell transplantation.
    Leuk Lymphoma. 2019 Sep 12:1-7. doi: 10.1080/10428194.2019.1660968.
    PubMed     Abstract available

  278. THUMMALAPALLI R, Sena LA, Probasco JC, Gladstone DE, et al
    Checkpoint inhibitor-induced autoimmune encephalitis reversed by rituximab after allogeneic bone marrow transplant in a patient with Hodgkin lymphoma.
    Leuk Lymphoma. 2019 Sep 10:1-3. doi: 10.1080/10428194.2019.1658104.

  279. MANCONI L, Coviello E, Canale F, Giannoni L, et al
    Dexamethasone, oxaliplatin and cytarabine (R-DHAOx) as salvage and stem cells mobilizing therapy in relapsed/refractory diffuse large B cell lymphomas.
    Leuk Lymphoma. 2019 Sep 4:1-7. doi: 10.1080/10428194.2019.1658102.
    PubMed     Abstract available

    August 2019
  280. MOREIRA J, Platanias LC, Adekola KUA
    It's all about the CD3+ T-cells: how circulating immune cell subset analyses can predict early relapse in Hodgkin lymphoma.
    Leuk Lymphoma. 2019 Aug 27:1-3. doi: 10.1080/10428194.2019.1646909.

  281. GO H, Jang JY, Kim CW, Huh J, et al
    Identification of microRNAs modulated by DNA hypomethylating drugs in extranodal NK/T-cell lymphoma.
    Leuk Lymphoma. 2019 Aug 23:1-9. doi: 10.1080/10428194.2019.1654096.
    PubMed     Abstract available

  282. FUKUHARA N, Yamamoto G, Tsujimura H, Chou T, et al
    Retreatment with brentuximab vedotin in patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large-cell lymphoma: a multicenter retrospective study.
    Leuk Lymphoma. 2019 Aug 22:1-5. doi: 10.1080/10428194.2019.1654100.

  283. DECKER DP, Egan PC, Zayac AS, Treaba DO, et al
    Treatment strategies and risk of central nervous system recurrence in high-grade B-cell and Burkitt lymphoma.
    Leuk Lymphoma. 2019 Aug 21:1-4. doi: 10.1080/10428194.2019.1654097.

  284. ZEREMSKI V, Fischer T, Schalk E
    Dose reduction and high-risk disease as risk factors for early death in primary CNS lymphoma.
    Leuk Lymphoma. 2019 Aug 8:1-3. doi: 10.1080/10428194.2019.1650176.

  285. ALBARMAWI H, Nagarajan M, Sun K, Gandhi AB, et al
    Costs associated with follicular lymphoma among individuals diagnosed with non-Hodgkin lymphoma: a longitudinal analysis using SEER-Medicare data.
    Leuk Lymphoma. 2019 Aug 7:1-9. doi: 10.1080/10428194.2019.1648804.
    PubMed     Abstract available

  286. ONG SY, Phipps C, Nagarajan C, Tang T, et al
    Cell-of-origin and bone marrow involvement increase specificity of defining patients with diffuse large B-cell lymphoma at high risk of CNS relapse: a study of 793 patients treated with chemoimmunotherapy in Asia.
    Leuk Lymphoma. 2019 Aug 5:1-3. doi: 10.1080/10428194.2019.1648805.

  287. GUNTHER JR, Park C, Dabaja BS, Milgrom SA, et al
    Radiation therapy for salivary gland MALT lymphoma: ultra-low dose treatment achieves encouraging early outcomes and spares salivary function().
    Leuk Lymphoma. 2019 Aug 2:1-5. doi: 10.1080/10428194.2019.1644333.

    July 2019
  288. TRACHTENBERG E, Gurion R, Mashiach T, Tadmor T, et al
    Recognizing severe fatigue and decline in quality of life in Hodgkin lymphoma survivors.
    Leuk Lymphoma. 2019 Jul 22:1-6. doi: 10.1080/10428194.2019.1641803.
    PubMed     Abstract available

  289. LOW SK, Zayan AH, Istanbuly O, Minh Duc NT, et al
    Prognostic factors and nomogram for survival prediction in patients with primary pulmonary lymphoma: a SEER population-based study.
    Leuk Lymphoma. 2019 Jul 19:1-11. doi: 10.1080/10428194.2019.1633636.
    PubMed     Abstract available

  290. YAMAGUCHI J, Chinen Y, Takimoto-Shimomura T, Nagata H, et al
    Prediction of delayed platelet engraftment after autologous stem cell transplantation for B-cell non-Hodgkin lymphoma.
    Leuk Lymphoma. 2019 Jul 18:1-8. doi: 10.1080/10428194.2019.1636982.
    PubMed     Abstract available

  291. WATANABE J, Natsumeda M, Kanemaru Y, Okada M, et al
    Comparison of circulating tumor DNA between body fluids in patients with primary central nervous system lymphoma.
    Leuk Lymphoma. 2019 Jul 15:1-3. doi: 10.1080/10428194.2019.1639169.

  292. KUZICH JA, Hutchison AP, Lim KJC, Smallbone P, et al
    Prognostic factors and the impact of frontline therapy in peripheral T-cell lymphoma: 10 years of 'real-world' experience from Western Australia.
    Leuk Lymphoma. 2019 Jul 15:1-9. doi: 10.1080/10428194.2019.1637865.
    PubMed     Abstract available

  293. FERRARINI I, Rigo A, Zamo A, Vinante F, et al
    Classical Hodgkin lymphoma cells may promote an IL-17-enriched microenvironment.
    Leuk Lymphoma. 2019 Jul 14:1-11. doi: 10.1080/10428194.2019.1636983.
    PubMed     Abstract available

  294. QI F, Chen B, Wang J, Lin X, et al
    Upfront radiation is essential for high-risk early-stage extranodal NK/T-cell lymphoma, nasal type: comparison of two sequential treatment modalities combining radiotherapy and GDP (gemcitabine, dexamethasone, and cisplatin) in the modern era.
    Leuk Lymphoma. 2019 Jul 12:1-10. doi: 10.1080/10428194.2019.1599111.
    PubMed     Abstract available

  295. HUETTL KS, Staiger AM, Stehle A, Bonzheim I, et al
    Peripheral T-cell lymphoma NOS arising in patients with classical Hodgkin lymphoma of cytotoxic phenotype.
    Leuk Lymphoma. 2019 Jul 10:1-4. doi: 10.1080/10428194.2019.1636987.

  296. OLLILA TA, Reagan JL, Olszewski AJ
    Clinical features and survival of patients with T-cell/histiocyte-rich large B-cell lymphoma: analysis of the National Cancer Data Base.
    Leuk Lymphoma. 2019 Jul 9:1-8. doi: 10.1080/10428194.2019.1639166.
    PubMed     Abstract available

  297. SALVI F, Luminari S, Tucci A, Massidda S, et al
    Bleomycin, vinblastine and dacarbazine combined with nonpegylated liposomal doxorubicin (MBVD) in elderly (>/=70 years) or cardiopathic patients with Hodgkin lymphoma: a phase-II study from Fondazione Italiana Linfomi (FIL).
    Leuk Lymphoma. 2019 Jul 8:1-9. doi: 10.1080/10428194.2019.1608529.
    PubMed     Abstract available

  298. DELAMAIN MT, Gomez GVB, Lourenco GJ, de Souza CA, et al
    Increased risk of Hodgkin lymphoma in males with inherited T lymphocyte receptor programed death-1 deficiency.
    Leuk Lymphoma. 2019 Jul 8:1-5. doi: 10.1080/10428194.2019.1636988.

  299. LOH KP, Baran A, Lee CY, Alshaibani A, et al
    Patients with diffuse large B-cell lymphoma requiring urgent treatment: its implication on trial design and interpretation.
    Leuk Lymphoma. 2019 Jul 8:1-4. doi: 10.1080/10428194.2019.1639172.

  300. GOLDSTEIN JS, Switchenko JM, Behera M, Flowers CR, et al
    Insurance status impacts overall survival in Burkitt lymphoma.
    Leuk Lymphoma. 2019 Jul 5:1-10. doi: 10.1080/10428194.2019.1623884.
    PubMed     Abstract available

  301. CANDELARIA M, Gonzalez DE, Delamain MT, Bar DO, et al
    Rituximab biosimilar RTXM83 versus reference rituximab in combination with CHOP as first-line treatment for diffuse large B-cell lymphoma: a randomized, double-blind study.
    Leuk Lymphoma. 2019 Jul 4:1-11. doi: 10.1080/10428194.2019.1633632.
    PubMed     Abstract available

  302. OON ML, Hoppe MM, Fan S, Phyu T, et al
    The contribution of MYC and PLK1 expression to proliferative capacity in diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2019 Jul 1:1-11. doi: 10.1080/10428194.2019.1633629.
    PubMed     Abstract available

  303. ANNIBALI O, Hohaus S, Marchesi F, Cantonetti M, et al
    The neutrophil/lymphocyte ratio >/=3.5 is a prognostic marker in diffuse large B-cell lymphoma: a retrospective analysis from the database of the Italian regional network 'Rete Ematologica del Lazio per i Linfomi' (RELLI).
    Leuk Lymphoma. 2019 Jul 1:1-9. doi: 10.1080/10428194.2019.1633628.
    PubMed     Abstract available

    June 2019
  304. HILAL T, Maguire A, Kosiorek HE, Rimsza LM, et al
    Clinical features and cell of origin subtyping using gene expression profiling in HIV-negative patients with primary central nervous system lymphoma.
    Leuk Lymphoma. 2019 Jun 27:1-3. doi: 10.1080/10428194.2019.1633637.

  305. ANDRAOS TY, Ayoub Z, Nastoupil LJ, Milgrom SA, et al
    Additional therapy improves outcomes in completely resected, limited-stage follicular lymphoma.
    Leuk Lymphoma. 2019 Jun 24:1-8. doi: 10.1080/10428194.2019.1627535.
    PubMed     Abstract available

  306. BAUES C, Gorgen H, Semrau R, Nast-Kolb B, et al
    Volumetric assessment of mediastinal lymphoma masses in Hodgkin lymphoma.
    Leuk Lymphoma. 2019 Jun 22:1-7. doi: 10.1080/10428194.2019.1623888.
    PubMed     Abstract available

  307. BEHDAD A, Boddy CS, Fought AJ, Taxter T, et al
    Survival outcomes of diffuse large B-cell lymphoma by association with concurrent or antecedent follicular lymphoma and double hit status.
    Leuk Lymphoma. 2019 Jun 21:1-6. doi: 10.1080/10428194.2019.1622099.
    PubMed     Abstract available

  308. PERSONETT HA, Barreto EF, McCullough KB, Dierkhising R, et al
    Impact of early rasburicase on incidence of clinical tumor lysis syndrome in lymphoma.
    Leuk Lymphoma. 2019 Jun 21:1-7. doi: 10.1080/10428194.2019.1574000.
    PubMed     Abstract available

  309. ZHONG C, Gragert L, Maiers M, Hill BT, et al
    The association between HLA and non-Hodgkin lymphoma subtypes, among a transplant-indicated population.
    Leuk Lymphoma. 2019 Jun 19:1-10. doi: 10.1080/10428194.2019.1617858.
    PubMed     Abstract available

  310. ACUNA-VILLAORDUNA A, Gonzalez-Lugo J, Ye BH, Adrianzen Herrera DA, et al
    High prevalence of pulmonary findings in computed tomographies of HTLV-1-infected patients with and without adult-T cell leukemia/lymphoma - implications for staging.
    Leuk Lymphoma. 2019 Jun 17:1-5. doi: 10.1080/10428194.2019.1627543.
    PubMed     Abstract available

  311. TOBIASSON M, Pandzic T, Cavelier L, Sander B, et al
    Angioimmunoblastic T-cell lymphoma and myelodysplastic syndrome with mutations in TET2, DNMT3 and CUX1 - azacitidine induces only lymphoma remission.
    Leuk Lymphoma. 2019 Jun 17:1-4. doi: 10.1080/10428194.2019.1627541.

  312. MILJKOVIC MD, Roschewski M, Dunleavy K, Wilson WH, et al
    Hybrid dosing of the cyclin-dependent kinase (CDK) inhibitor flavopiridol in relapsed/refractory mantle cell lymphoma and diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2019 Jun 17:1-4. doi: 10.1080/10428194.2019.1627540.

  313. SHAW J, Harvey C, Richards C, Kim C, et al
    Temporal trends in treatment and survival of older adult diffuse large B-Cell lymphoma patients in the SEER-Medicare linked database.
    Leuk Lymphoma. 2019 Jun 12:1-9. doi: 10.1080/10428194.2019.1623886.
    PubMed     Abstract available

  314. SETHI TK, Kovach AE, Grover NS, Huang LC, et al
    Clinicopathologic correlates of MYD88 L265P mutation and programmed cell death (PD-1) pathway in primary central nervous system lymphoma.
    Leuk Lymphoma. 2019 Jun 11:1-10. doi: 10.1080/10428194.2019.1620942.
    PubMed     Abstract available

  315. MA H, Bhagat G, O'Connor OA
    A peripheral T-cell lymphoma (PTCL) arising as a post-transplant lymphoproliferative disorder: efficacy of pralatrexate in primary refractory disease and review of the literature.
    Leuk Lymphoma. 2019 Jun 11:1-4. doi: 10.1080/10428194.2019.1622102.

  316. VASSEUR L, Lara D, Clappier E, Gillebert Q, et al
    Common clonal origin of an EBV-positive diffuse large B cell lymphoma and a chronic myelomonocytic leukemia.
    Leuk Lymphoma. 2019 Jun 11:1-3. doi: 10.1080/10428194.2019.1627539.

  317. PARK BB, Kim WS, Suh C, Hong JY, et al
    A phase II trial of bendamustine, carboplatin, and dexamethasone for refractory or relapsed peripheral T-cell lymphoma (BENCART trial).
    Leuk Lymphoma. 2019 Jun 6:1-7. doi: 10.1080/10428194.2019.1622100.
    PubMed     Abstract available

  318. PALMARSDOTTIR R, Kiesbye Ovlisen A, Tang Severinsen M, Glimelius I, et al
    Socioeconomic impact of Hodgkin lymphoma in adult patients: a systematic literature review.
    Leuk Lymphoma. 2019 Jun 6:1-16. doi: 10.1080/10428194.2019.1613538.
    PubMed     Abstract available

  319. ABADI U, Peled L, Gurion R, Rotman-Pikielny P, et al
    Prevalence and clinical significance of hypercalcemia at diagnosis in diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2019 Jun 6:1-5. doi: 10.1080/10428194.2019.1620946.
    PubMed     Abstract available

  320. ELMAAGACLI AH, Salwender H, Jehn C, Dahmash F, et al
    Strong expression of SLAMF7 in natural killer/T-cell lymphoma and large granular lymphocyte leukemia - a prominent biomarker and potential target for anti-SLAMF7 antibody therapy.
    Leuk Lymphoma. 2019 Jun 4:1-4. doi: 10.1080/10428194.2019.1623887.

    May 2019
  321. DINH A, Palmer MB, Svoboda J, Hogan JJ, et al
    Lenalidomide-induced tubulointerstitial nephritis in Hodgkin lymphoma.
    Leuk Lymphoma. 2019 May 24:1-3. doi: 10.1080/10428194.2019.1616187.

  322. MARTIN P, Ruan J, Furman R, Rutherford S, et al
    A phase I trial of palbociclib plus bortezomib in previously treated mantle cell lymphoma.
    Leuk Lymphoma. 2019 May 23:1-5. doi: 10.1080/10428194.2019.1612062.
    PubMed     Abstract available

  323. FOSS FM, Parker TL, Girardi M, Li A, et al
    Effect of leucovorin administration on mucositis and skin reactions in patients with peripheral T-cell lymphoma or cutaneous T-cell lymphoma treated with pralatrexate.
    Leuk Lymphoma. 2019 May 23:1-4. doi: 10.1080/10428194.2019.1612061.
    PubMed     Abstract available

  324. BEST S, Liu T, Bruss N, Kittai A, et al
    Pharmacologic inhibition of the ubiquitin-activating enzyme induces ER stress and apoptosis in chronic lymphocytic leukemia and ibrutinib-resistant mantle cell lymphoma cells.
    Leuk Lymphoma. 2019 May 21:1-5. doi: 10.1080/10428194.2019.1616190.
    PubMed     Abstract available

    PET beyond Deauville in diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2019 May 20:1-2. doi: 10.1080/10428194.2019.1599115.

  326. SHIMAZU Y, Nohgawa M
    Plasma exchange following mogamulizumab therapy before bone marrow transplantation in refractory adult T-cell leukemia-lymphoma.
    Leuk Lymphoma. 2019 May 20:1-2. doi: 10.1080/10428194.2019.1616188.

  327. PING N, Qu C, Bai L, Kang L, et al
    Successful chimeric antigen receptor T cell therapy in a case of primary testicular diffuse large-B-cell lymphoma with central nervous system progression.
    Leuk Lymphoma. 2019 May 14:1-3. doi: 10.1080/10428194.2019.1605507.

  328. HORGAN C, Elmoamly S, McIlroy G, Davies D, et al
    Reduced intensity alemtuzumab-containing allogeneic stem cell transplantation for relapsed/refractory low grade lymphoma: reflections on a single center experience.
    Leuk Lymphoma. 2019 May 13:1-3. doi: 10.1080/10428194.2019.1607323.

  329. QI SN, Xu LM, Yuan ZY, Wu T, et al
    Effect of primary tumor invasion on treatment and survival in extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: a multicenter study from the China Lymphoma Collaborative Group (CLCG).
    Leuk Lymphoma. 2019 May 7:1-10. doi: 10.1080/10428194.2019.1602265.
    PubMed     Abstract available

  330. FERREIRA GA, Thome CH, Simao AMS, Scheucher PS, et al
    The lipid raft protein NTAL participates in AKT signaling in mantle cell lymphoma.
    Leuk Lymphoma. 2019 May 7:1-11. doi: 10.1080/10428194.2019.1607326.
    PubMed     Abstract available

  331. JAKOBSEN LH, Biccler JL, Brown PN, Jorgensen JM, et al
    No differential overall or relative survival effect of rituximab in male and female patients with diffuse large B-cell lymphoma: a Danish population-based study of 3783 patients.
    Leuk Lymphoma. 2019 May 6:1-4. doi: 10.1080/10428194.2019.1602264.

  332. MOLETI ML, Al-Jadiry MF, Shateh WA, Al-Darraji AF, et al
    Long-term results with the adapted LMB 96 protocol in children with B-cell non Hodgkin lymphoma treated in Iraq: comparison in two subsequent cohorts of patients.
    Leuk Lymphoma. 2019;60:1224-1233.
    PubMed     Abstract available

    April 2019
  333. ROBAK T, Smolewski P, Robak P, Dreyling M, et al
    Mantle cell lymphoma: therapeutic options in transplant-ineligible patients.
    Leuk Lymphoma. 2019 Apr 25:1-13. doi: 10.1080/10428194.2019.1605511.
    PubMed     Abstract available

  334. SUN M, Su W, Qian J, Meng H, et al
    The prognostic value of toll-like receptor5 and programmed cell death-ligand1 in patients with peripheral T-cell non-Hodgkin lymphoma.
    Leuk Lymphoma. 2019 Apr 24:1-12. doi: 10.1080/10428194.2019.1602266.
    PubMed     Abstract available

  335. GREENBAUM U, Levi I, Madmoni O, Lior Y, et al
    The prognostic significance of bone marrow involvement in diffuse large B cell lymphoma according to the flow cytometry.
    Leuk Lymphoma. 2019 Apr 24:1-6. doi: 10.1080/10428194.2019.1587755.
    PubMed     Abstract available

  336. GARCIAZ S, Loschi M, De Masson A, Biard L, et al
    Brentuximab vedotin as a bridge to allogeneic stem-cell transplantation for refractory or relapsing patients with CD30 positive anaplastic or T-cell non-Hodgkin lymphomas: a study on behalf of the SFGM-TC.
    Leuk Lymphoma. 2019 Apr 24:1-4. doi: 10.1080/10428194.2019.1599112.

  337. VON TRESCKOW B, Fanale M, Ardeshna KM, Chen R, et al
    Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphoma.
    Leuk Lymphoma. 2019 Apr 23:1-7. doi: 10.1080/10428194.2019.1602262.
    PubMed     Abstract available

  338. VIJENTHIRA A, Maganti M, Kukreti V, Kuruvilla J, et al
    Outcomes of patients with relapsed low-grade lymphoma retreated with rituximab are similar to rituximab naive patients.
    Leuk Lymphoma. 2019 Apr 18:1-4. doi: 10.1080/10428194.2019.1585837.

  339. KEANE C, Yoon Cheah C
    Designing optimal prognostic models for diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2019 Apr 16:1-3. doi: 10.1080/10428194.2019.1599117.

  340. JURCZAK W, M Gruszka A, Sowa Staszczak A, Dlugosz-Danecka M, et al
    Consolidation with (90)Y ibritumomab tiuxetan radioimmunotherapy in mantle cell lymphoma patients ineligible for high dose therapy: results of the phase II multicentre Polish Lymphoma Research Group trial, after 8-year long follow-up.
    Leuk Lymphoma. 2019 Apr 9:1-8. doi: 10.1080/10428194.2019.1602261.
    PubMed     Abstract available

  341. UMINO K, Fujiwara SI, Ikeda T, Kawaguchi SI, et al
    Impact of the soluble interleukin-2 receptor level in the relapsed or refractory phase on the clinical outcome of patients with diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2019 Apr 5:1-8. doi: 10.1080/10428194.2018.1564824.
    PubMed     Abstract available

  342. LIU J, Hong J, Ahn KS, Go J, et al
    ERK-dependent IL-6 positive feedback loop mediates resistance against a combined treatment using danusertib and BKM120 in Burkitt lymphoma cell lines.
    Leuk Lymphoma. 2019 Apr 5:1-9. doi: 10.1080/10428194.2019.1594211.
    PubMed     Abstract available

  343. BICCLER JL, Savage KJ, Brown PDN, Jorgensen J, et al
    Risk of death, relapse or progression, and loss of life expectancy at different progression-free survival milestones in primary central nervous system lymphoma.
    Leuk Lymphoma. 2019 Apr 3:1-8. doi: 10.1080/10428194.2019.1594219.
    PubMed     Abstract available

  344. AYOUB Z, Andraos T, Milgrom SA, Pinnix CC, et al
    Limited stage grade 3 follicular lymphoma patients can experience favorable outcomes with combined modality therapy.
    Leuk Lymphoma. 2019 Apr 3:1-9. doi: 10.1080/10428194.2019.1597081.
    PubMed     Abstract available

  345. SORIGUE M, Bishton M, Domingo-Domenech E, McMillan A, et al
    Refractoriness to rituximab-based therapy and elevated serum B2-microglobulin predict for inferior survival in marginal zone lymphoma.
    Leuk Lymphoma. 2019 Apr 3:1-8. doi: 10.1080/10428194.2019.1594212.
    PubMed     Abstract available

  346. SHALLIS RM, Gleeson S, Azar M, Malinis M, et al
    Allogeneic stem cell transplantation and combination antiretroviral therapy: cautions, complications, and considerations.
    Leuk Lymphoma. 2019 Apr 3:1-4. doi: 10.1080/10428194.2019.1594221.

    March 2019
  347. CHO SK, McCombs J, Punwani N, Lam J, et al
    Complications and hospital costs during hematopoietic stem cell transplantation for non-Hodgkin lymphoma in the United States.
    Leuk Lymphoma. 2019 Mar 8:1-7. doi: 10.1080/10428194.2019.1581932.
    PubMed     Abstract available

  348. GOPALSAMY SN, Rosenthal KM, Ayers AA, Goy A, et al
    Clinical impact of Internet-based tools to guide therapeutic decisions for mantle cell lymphoma.
    Leuk Lymphoma. 2019 Mar 8:1-9. doi: 10.1080/10428194.2019.1574006.
    PubMed     Abstract available

  349. JANTUNEN E, Varmavuo V, Pelkonen J, Valtola J, et al
    Importance of early immune recovery after autologous hematopoietic cell transplantation in lymphoma patients.
    Leuk Lymphoma. 2019 Mar 7:1-7. doi: 10.1080/10428194.2019.1581929.
    PubMed     Abstract available

  350. HARRINGTON BK, Wheeler E, Hornbuckle K, Y Shana'ah A, et al
    Modulation of immune checkpoint molecule expression in mantle cell lymphoma.
    Leuk Lymphoma. 2019 Mar 1:1-10. doi: 10.1080/10428194.2019.1569231.
    PubMed     Abstract available

  351. BROCCOLI A, Forti Parri SN, Pellegrini C, Casadei B, et al
    Histological findings in patients with suspected mediastinal lymphoma relapse according to positive positron emission tomography scan during follow-up: a large retrospective analysis in 96 patients.
    Leuk Lymphoma. 2019 Mar 1:1-8. doi: 10.1080/10428194.2019.1581931.
    PubMed     Abstract available

    February 2019
  352. SHIN SH, Kim YJ, Lee D, Cho D, et al
    Analysis of circulating tumor DNA by targeted ultra-deep sequencing across various non-Hodgkin lymphoma subtypes.
    Leuk Lymphoma. 2019 Feb 18:1-10. doi: 10.1080/10428194.2019.1573998.
    PubMed     Abstract available

  353. PHILLIPS EH, Devereux S, Radford J, Mir N, et al
    Toxicity and efficacy of alemtuzumab combined with CHOP for aggressive T-cell lymphoma: a phase 1 dose-escalation trial.
    Leuk Lymphoma. 2019 Feb 18:1-4. doi: 10.1080/10428194.2019.1576870.

  354. MARTIN P
    The optimal chemotherapy regimen for primary mediastinal B-cell lymphoma: we may never know.
    Leuk Lymphoma. 2019 Feb 8:1-2. doi: 10.1080/10428194.2018.1535119.

  355. OKA S, Ono K, Nohgawa M
    Successful treatment with mogamulizumab of refractory/relapsed angioimmunoblastic T-cell lymphoma following autologous stem cell transplantation.
    Leuk Lymphoma. 2019 Feb 8:1-3. doi: 10.1080/10428194.2018.1537489.

  356. PHILIP J, Collins A, Ritchie D, Le B, et al
    Patterns of end-of-life hospital care for patients with non-Hodgkin lymphoma: exploring the landscape.
    Leuk Lymphoma. 2019 Feb 7:1-9. doi: 10.1080/10428194.2018.1564047.
    PubMed     Abstract available

  357. LEPIK KV, Mikhailova NB, Moiseev IS, Kondakova EV, et al
    Nivolumab for the treatment of relapsed and refractory classical Hodgkin lymphoma after ASCT and in ASCT-naive patients.
    Leuk Lymphoma. 2019 Feb 4:1-4. doi: 10.1080/10428194.2019.1573368.

  358. BLOMBERY P, Dawson SJ
    Circulating tumor DNA for disease monitoring in the era of CAR T-cell therapy.
    Leuk Lymphoma. 2019;60:279-280.

    Can rituximab unlock the innate potential of checkpoint blockade in the CNS?
    Leuk Lymphoma. 2019;60:281-283.

  360. MCCARTER SJ, Vijayvargiya P, Sidana S, Nault AM, et al
    A case of ibrutinib-associated aspergillosis presenting with central nervous system, myocardial, pulmonary, intramuscular, and subcutaneous abscesses.
    Leuk Lymphoma. 2019;60:559-561.

  361. BIGGI A, Bergesio F, Chauvie S
    Monitoring response in lymphomas: qualitative, quantitative, or what else?
    Leuk Lymphoma. 2019;60:302-308.
    PubMed     Abstract available

    January 2019
  362. SALLES GA, Pettengell R, Cordoba R, Dlugosz-Danecka M, et al
    Treatment of aggressive B-cell non-Hodgkin lymphoma beyond frontline therapy in patients not eligible for stem cell transplantation: a structured review.
    Leuk Lymphoma. 2019 Jan 31:1-16. doi: 10.1080/10428194.2018.1564828.
    PubMed     Abstract available

  363. KAHL BS, Dreyling M, Gordon LI, Martin P, et al
    Recent advances and future directions in mantle cell lymphoma research: report of the 2018 mantle cell lymphoma consortium workshop.
    Leuk Lymphoma. 2019 Jan 30:1-13. doi: 10.1080/10428194.2019.1571205.
    PubMed     Abstract available

  364. MARCHESELLI R, Franceschetto A, Sacchi S, Bari A, et al
    The prognostic role of end of treatment FDG-PET-CT in patients with diffuse large B cell lymphoma can be improved by considering it with absolute monocyte count at diagnosis.
    Leuk Lymphoma. 2019 Jan 28:1-7. doi: 10.1080/10428194.2018.1564049.
    PubMed     Abstract available

  365. GOLDSCHMIDT N, Horowitz NA, Hefetz V, Darawshy F, et al
    Addition of high-dose methotrexate to standard treatment for patients with high-risk diffuse large B-cell lymphoma contributes to improved freedom from progression and survival but does not prevent central nervous system relapse.
    Leuk Lymphoma. 2019 Jan 28:1-9. doi: 10.1080/10428194.2018.1564823.
    PubMed     Abstract available

  366. WANG J, Van Den Berg D, Hwang AE, Weisenberger D, et al
    DNA methylation patterns of adult survivors of adolescent/young adult Hodgkin lymphoma compared to their unaffected monozygotic twin.
    Leuk Lymphoma. 2019 Jan 22:1-9. doi: 10.1080/10428194.2018.1533128.
    PubMed     Abstract available

  367. CLAUSEN MR, Ulrichsen SP, Larsen TS, Poulsen CB, et al
    Depth of neutrophil nadir after first cycle of R-CHOP predicts outcome in diffuse large B-cell lymphoma - a nationwide population-based cohort study.
    Leuk Lymphoma. 2019 Jan 22:1-8. doi: 10.1080/10428194.2018.1554863.
    PubMed     Abstract available

  368. MESSMER M, Tsai HL, Varadhan R, Swinnen LJ, et al
    R-CHOP without radiation in frontline management of primary mediastinal B-cell lymphoma.
    Leuk Lymphoma. 2019 Jan 18:1-5. doi: 10.1080/10428194.2018.1519812.
    PubMed     Abstract available

  369. NEVEL KS, Pentsova E, Daras M
    Clinical presentation, treatment, and outcomes of patients with central nervous system involvement in extranodal natural killer/T-cell lymphoma.
    Leuk Lymphoma. 2019 Jan 16:1-8. doi: 10.1080/10428194.2018.1551541.
    PubMed     Abstract available

  370. PATHAK P, Perimbeti S, Ames A, Moskowitz AJ, et al
    Guillain Barre syndrome heralding the diagnosis of angioimmunoblastic T-cell lymphoma.
    Leuk Lymphoma. 2019 Jan 16:1-4. doi: 10.1080/10428194.2018.1553299.

  371. WANG XX, Li PF, Bai B, Gao Y, et al
    Differential clinical significance of pre-, interim-, and post-treatment plasma Epstein-Barr virus DNA load in NK/T-cell lymphoma treated with P-GEMOX protocol.
    Leuk Lymphoma. 2019 Jan 16:1-9. doi: 10.1080/10428194.2018.1563690.
    PubMed     Abstract available

  372. CHEN SH, Chen JS, Jou ST, Wu KH, et al
    Outcome and prognosis of anaplastic large cell lymphoma in children: a report from the Taiwan Pediatric Oncology Group.
    Leuk Lymphoma. 2019 Jan 15:1-8. doi: 10.1080/10428194.2018.1562182.
    PubMed     Abstract available

  373. ANSELL SM
    Immunophenotype switching in cutaneous T-cell lymphoma: nature or nurture?
    Leuk Lymphoma. 2019 Jan 11:1-2. doi: 10.1080/10428194.2018.1543887.

  374. GUZAUSKAS GF, Masaquel A, Thuresson PO, Dawson K, et al
    Obinutuzumab plus chemotherapy followed by obinutuzumab monotherapy is cost-effective vs. rituximab plus chemotherapy followed by rituximab monotherapy for previously untreated follicular lymphoma patients in the United States.
    Leuk Lymphoma. 2019 Jan 11:1-9. doi: 10.1080/10428194.2018.1551532.
    PubMed     Abstract available

  375. BOHN JP, Willenbacher W, Haas G, Peschel I, et al
    Pomalidomide in primary intraocular lymphoma.
    Leuk Lymphoma. 2019 Jan 11:1-3. doi: 10.1080/10428194.2018.1538508.

  376. RITTER AJ, Goldstein JS, Ayers AA, Flowers CR, et al
    Rural and urban patients with diffuse large B-cell and follicular lymphoma experience reduced overall survival: a National Cancer DataBase study.
    Leuk Lymphoma. 2019 Jan 11:1-12. doi: 10.1080/10428194.2018.1546855.
    PubMed     Abstract available

  377. AL-MANSOUR Z, Li H, Cook JR, Constine LS, et al
    Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis.
    Leuk Lymphoma. 2019 Jan 10:1-8. doi: 10.1080/10428194.2018.1563691.
    PubMed     Abstract available

  378. MARECKOVA A, Malcikova J, Tom N, Pal K, et al
    ATM and TP53 mutations show mutual exclusivity but distinct clinical impact in mantle cell lymphoma patients.
    Leuk Lymphoma. 2019 Jan 10:1-9. doi: 10.1080/10428194.2018.1542144.
    PubMed     Abstract available

    December 2018
  379. HAPGOOD G, Stone JM, Zannino D, George A, et al
    A phase II study of a modified hyper-CVAD frontline therapy for patients with adverse risk diffuse large B-cell and peripheral T-cell non-Hodgkin lymphoma.
    Leuk Lymphoma. 2018 Dec 14:1-8. doi: 10.1080/10428194.2018.1516873.
    PubMed     Abstract available

  380. RUEDA A, Calvo V, Casanova M, Rodriguez-Abreu D, et al
    Efficacy of the combination of rituximab-bendamustine as a second-line treatment in patients with follicular lymphoma who progress after immunochemotherapy: a phase II trial of the Spanish Lymphoma Oncology Group.
    Leuk Lymphoma. 2018 Dec 5:1-4. doi: 10.1080/10428194.2018.1542147.

  381. STEVENSON JKR, Qiao Y, Chan KKW, Beca J, et al
    Improved survival in overweight and obese patients with aggressive B-cell lymphoma treated with rituximab-containing chemotherapy for curative intent.
    Leuk Lymphoma. 2018 Dec 5:1-9. doi: 10.1080/10428194.2018.1538509.
    PubMed     Abstract available

  382. KREISSL S, Goergen H, Muller H, Meissner J, et al
    Survivors' perspectives on risks and benefits of Hodgkin lymphoma treatment: results of a survey by the German Hodgkin Study Group.
    Leuk Lymphoma. 2018 Dec 3:1-10. doi: 10.1080/10428194.2018.1540781.
    PubMed     Abstract available

  383. MAJOR A, Jackson MW, Smith DE, Kamdar M, et al
    Inferior outcomes and treatment disparities in elderly patients with classical Hodgkin lymphoma: a national cancer data base analysis.
    Leuk Lymphoma. 2018 Dec 3:1-10. doi: 10.1080/10428194.2018.1522435.
    PubMed     Abstract available

    November 2018
  384. TSENG YD, Ng AK, Wirth A
    New tools of the trade: parsing out the role of radiotherapy for early-stage diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2018 Nov 27:1-3. doi: 10.1080/10428194.2018.1531397.

  385. SUN Y, Murty VV, Leeman-Neill R, Soderquist C, et al
    Cytogenetic analysis of adult T-Cell leukemia/lymphoma: evaluation of a Caribbean cohort.
    Leuk Lymphoma. 2018 Nov 27:1-3. doi: 10.1080/10428194.2018.1538506.

  386. ITO Y, Umezu T, Tadokoro K, Saito Y, et al
    BIM deletion polymorphism accounts for lack of favorable outcome in Japanese females with follicular lymphoma.
    Leuk Lymphoma. 2018 Nov 27:1-6. doi: 10.1080/10428194.2018.1529310.
    PubMed     Abstract available

  387. GRASS GD, Mills MN, Ahmed KA, Liveringhouse CL, et al
    Radiotherapy for early stage diffuse large B-cell lymphoma with or without double or triple hit genetic alterations.
    Leuk Lymphoma. 2018 Nov 20:1-8. doi: 10.1080/10428194.2018.1506586.
    PubMed     Abstract available

  388. CHATURVEDI NK, Hatch ND, Sutton GL, Kling M, et al
    A novel approach to eliminate therapy-resistant mantle cell lymphoma: synergistic effects of Vorinostat with Palbociclib.
    Leuk Lymphoma. 2018 Nov 14:1-10. doi: 10.1080/10428194.2018.1520986.
    PubMed     Abstract available

  389. ZAJAC-SPYCHALA O, Wachowiak J, Szmydki-Baran A, Hutnik L, et al
    Infectious complications in children treated for hodgkin and non-hodgkin lymphomas in polish pediatric leukemia/lymphoma study group: incidence, epidemiology and etiology.
    Leuk Lymphoma. 2018 Nov 5:1-9. doi: 10.1080/10428194.2018.1466293.
    PubMed     Abstract available

    October 2018
  390. TANG R, Su C, Bai HX, Zeng Z, et al
    Association of insurance status with survival in patients with cutaneous T-cell lymphoma.
    Leuk Lymphoma. 2018 Oct 16:1-8. doi: 10.1080/10428194.2018.1520987.
    PubMed     Abstract available

  391. ZINZANI PL, Santoro A, Chiti A, Lastoria S, et al
    Italian expert panel consensus statement on the optimal use of PD-1 blockade therapy in classical Hodgkin lymphoma.
    Leuk Lymphoma. 2018 Oct 15:1-10. doi: 10.1080/10428194.2018.1519808.
    PubMed     Abstract available

  392. BAPTISTA MJ, Tapia G, Morgades M, Muncunill J, et al
    Using the Lymph2Cx assay for assessing cell-of-origin subtypes of HIV-related diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2018 Oct 15:1-5. doi: 10.1080/10428194.2018.1512711.

  393. FARRUGGIA P, Puccio G, Locatelli F, Vetro M, et al
    Classical pediatric Hodgkin lymphoma in very young patients: the Italian experience.
    Leuk Lymphoma. 2018 Oct 10:1-7. doi: 10.1080/10428194.2018.1493732.
    PubMed     Abstract available

  394. REIMAN T, Savage KJ, Crump M, Cheung MC, et al
    A phase I study of romidepsin, gemcitabine, dexamethasone and cisplatin combination therapy in the treatment of peripheral T-cell and diffuse large B-cell lymphoma; the Canadian cancer trials group LY.15 studydagger.
    Leuk Lymphoma. 2018 Oct 10:1-8. doi: 10.1080/10428194.2018.1515937.
    PubMed     Abstract available

  395. LE CLEF Q, Ortega-Sanchez G, Dirnhofer S, Tzankov A, et al
    T-lymphoblastic lymphoma after previous thymoma: how NGS helps establishing the diagnosis and procures new insights.
    Leuk Lymphoma. 2018 Oct 10:1-4. doi: 10.1080/10428194.2018.1520993.

  396. WU X, Hsu DK, Wang KH, Huang Y, et al
    IL-10 is overexpressed in human cutaneous T-cell lymphoma and is required for maximal tumor growth in a mouse model.
    Leuk Lymphoma. 2018 Oct 2:1-9. doi: 10.1080/10428194.2018.1516037.
    PubMed     Abstract available

  397. ANDERSEN MD, Kamper P, d'Amore A, Clausen M, et al
    The incidence of bleomycin induced lung toxicity is increased in Hodgkin lymphoma patients over 45 years exposed to granulocyte-colony stimulating growth factor (dagger).
    Leuk Lymphoma. 2018 Oct 2:1-7. doi: 10.1080/10428194.2018.1515939.
    PubMed     Abstract available

  398. BADAR T, Hamadani M, Bachanova V, Maddocks KJ, et al
    Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin.
    Leuk Lymphoma. 2018 Oct 2:1-7. doi: 10.1080/10428194.2018.1515944.
    PubMed     Abstract available

  399. LIU YZ, Xue K, Wang BS, Li CY, et al
    The size and depth of lesions measured by endoscopic ultrasonography are novel prognostic factors of primary gastric diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2018 Oct 2:1-6. doi: 10.1080/10428194.2018.1515942.
    PubMed     Abstract available

  400. CHEN YF, Chang CH, Huang ZN, Su YC, et al
    The JAK inhibitor antcin H exhibits direct anticancer activity while enhancing chemotherapy against LMP1-expressed lymphoma.
    Leuk Lymphoma. 2018 Oct 2:1-11. doi: 10.1080/10428194.2018.1512709.
    PubMed     Abstract available

  401. SHARMAN JP, Forero-Torres A, Costa LJ, Flinn IW, et al
    Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study.
    Leuk Lymphoma. 2018 Oct 2:1-10. doi: 10.1080/10428194.2018.1515940.
    PubMed     Abstract available

  402. GOYAL RK, Nagar SP, Kabadi SM, Kaye JA, et al
    Adverse events, resource use, and economic burden associated with mantle cell lymphoma: a real-world assessment of privately insured patients in the United States.
    Leuk Lymphoma. 2018 Oct 2:1-9. doi: 10.1080/10428194.2018.1509320.
    PubMed     Abstract available

  403. DHEUR MS, Poirel HA, Ameye G, Tilman G, et al
    Characterization of two new high-grade B-cell lymphoma cell lines with MYC and BCL2 rearrangements that are suitable for in vitro drug sensitivity studies.
    Leuk Lymphoma. 2018 Oct 2:1-10. doi: 10.1080/10428194.2018.1508663.
    PubMed     Abstract available

    September 2018
  404. SHAO C, Liu J, Zhou W, Raut MK, et al
    Treatment patterns, health care resource utilization, and costs in patients with relapsed/refractory Hodgkin lymphoma treated with brentuximab vedotin.
    Leuk Lymphoma. 2018 Sep 20:1-8. doi: 10.1080/10428194.2018.1508665.
    PubMed     Abstract available

  405. CAMUS V, Dubois S, Jardin F, Tilly H, et al
    Prognostic impact of diagnosis to treatment interval (DTI) in diffuse large B-cell lymphoma patients: a real-life monocentric study.
    Leuk Lymphoma. 2018 Sep 20:1-3. doi: 10.1080/10428194.2018.1508671.

  406. PROVENCIO M, Franco F, Gomez-Codina J, Quero Blanco C, et al
    Consolidation treatment with yttrium-90 ibritumomab tiuxetan after new induction regimen in advanced stage follicular lymphoma: update results from the Spanish Lymphoma Oncology Group trial after a median follow-up of 8.5-years.
    Leuk Lymphoma. 2018 Sep 20:1-4. doi: 10.1080/10428194.2018.1509322.

  407. CENCINI E, Fabbri A, Schiattone L, Bocchia M, et al
    Efficacy and safety of rituximab plus bendamustine for gastric marginal zone lymphoma.
    Leuk Lymphoma. 2018 Sep 20:1-3. doi: 10.1080/10428194.2018.1504938.

  408. UMINO K, Fujiwara SI, Minakata D, Yamamoto C, et al
    Prognostic impact of serum soluble interleukin-2 receptor level at diagnosis in elderly patients with diffuse large B-cell lymphoma treated with R-CHOP.
    Leuk Lymphoma. 2018 Sep 6:1-8. doi: 10.1080/10428194.2018.1504939.
    PubMed     Abstract available

  409. GANZEL C, Silverman B, Chemtob D, Ben Shoham A, et al
    The risk of tuberculosis in cancer patients is greatest in lymphoma and myelodysplastic syndrome/myeloproliferative neoplasm: a large population-based cohort study.
    Leuk Lymphoma. 2018 Sep 6:1-6. doi: 10.1080/10428194.2018.1499904.
    PubMed     Abstract available

  410. OBR A, Prochazka V, Papajik T, Klener P Jr, et al
    Maintenance rituximab in newly diagnosed mantle cell lymphoma patients: a real world analysis from the Czech lymphoma study group registry(dagger).
    Leuk Lymphoma. 2018 Sep 6:1-8. doi: 10.1080/10428194.2018.1508672.
    PubMed     Abstract available

  411. CICHOWSKA-CWALINSKA N, Dutka M, Klapkowski A, Peksa R, et al
    The role of radiotherapy in the management of primary cardiac lymphoma a case report and the literature review.
    Leuk Lymphoma. 2018 Sep 6:1-5. doi: 10.1080/10428194.2018.1509321.

  412. ISE M, Kageyama H, Araki A, Itami M, et al
    Identification of a novel GORASP2-ALK fusion in an ALK-positive large B-cell lymphoma.
    Leuk Lymphoma. 2018 Sep 6:1-5. doi: 10.1080/10428194.2018.1493731.

  413. OHNO H, Nakagawa M, Kishimori C, Fukutsuka K, et al
    A rare MYC/BCL3 double-translocation and protein-expression in a diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2018 Sep 6:1-4. doi: 10.1080/10428194.2018.1498493.

  414. ROTOLO A, Karadimitris A, Ruella M
    Building upon the success of CART19: chimeric antigen receptor T cells for hematologic malignancies.
    Leuk Lymphoma. 2018;59:2040-2055.
    PubMed     Abstract available

    August 2018
  415. WALEWSKI J, Paszkiewicz-Kozik E, Borsaru G, Hellmann A, et al
    Resminostat in patients with relapsed or refractory Hodgkin lymphoma: results of the phase II SAPHIRE study.
    Leuk Lymphoma. 2018 Aug 30:1-10. doi: 10.1080/10428194.2018.1492122.
    PubMed     Abstract available

  416. BESSI L, Viailly PJ, Bohers E, Ruminy P, et al
    Somatic mutations of cell-free circulating DNA detected by targeted next-generation sequencing and digital droplet PCR in classical Hodgkin lymphoma.
    Leuk Lymphoma. 2018 Aug 2:1-5. doi: 10.1080/10428194.2018.1492123.

  417. ROBERTS ZJ, Better M, Bot A, Roberts MR, et al
    Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL.
    Leuk Lymphoma. 2018;59:1785-1796.
    PubMed     Abstract available

    July 2018
  418. QIN W, Yuan Q, Wu J, Yu H, et al
    Prognostic value of pre-therapy C-reactive protein level in diffuse large B-cell lymphoma: a meta-analysis.
    Leuk Lymphoma. 2018 Jul 22:1-9. doi: 10.1080/10428194.2018.1482540.
    PubMed     Abstract available

  419. BARP A, Gilardin L, Afanasiev V, Delorme C, et al
    Subacute inflammatory demyelinating polyradiculoneuropathy complicating relapsing Hodgkin lymphoma: another immune-related adverse event of the anti-PD1 therapy?
    Leuk Lymphoma. 2018 Jul 22:1-3. doi: 10.1080/10428194.2018.1485912.

  420. AMBADY P, Szidonya L, Firkins J, James J, et al
    Combination immunotherapy as a non-chemotherapy alternative for refractory or recurrent CNS lymphoma.
    Leuk Lymphoma. 2018 Jul 22:1-4. doi: 10.1080/10428194.2018.1480771.

  421. BRANDT A, Matschke J, Fehrle W, von Wenserski L, et al
    A significant proportion of patients with primary central nervous system lymphoma harbor clonal bone marrow B-cells.
    Leuk Lymphoma. 2018 Jul 22:1-7. doi: 10.1080/10428194.2018.1482538.
    PubMed     Abstract available

  422. CASTELLO A, Grizzi F, Qehajaj D, Rahal D, et al
    (18)F-FDG PET/CT for response assessment in Hodgkin lymphoma undergoing immunotherapy with checkpoint inhibitors.
    Leuk Lymphoma. 2018 Jul 22:1-9. doi: 10.1080/10428194.2018.1488254.
    PubMed     Abstract available

  423. WROBEL T, Biecek P, Rybka J, Szulgo A, et al
    Hodgkin lymphoma of the elderly patients: a retrospective multicenter analysis from the Polish Lymphoma Research Group().
    Leuk Lymphoma. 2018 Jul 6:1-8. doi: 10.1080/10428194.2018.1482539.
    PubMed     Abstract available

  424. LIM SW, Ryu KJ, Lee H, Ko YH, et al
    Serum IL18 is associated with hemophagocytosis and poor survival in extranodal natural killer/T-cell lymphoma.
    Leuk Lymphoma. 2018 Jul 6:1-9. doi: 10.1080/10428194.2018.1480772.
    PubMed     Abstract available

  425. TANEJA A, Jones J, Pittaluga S, Maric I, et al
    Richter transformation to Hodgkin lymphoma on Bruton's tyrosine kinase inhibitor therapy.
    Leuk Lymphoma. 2018 Jul 6:1-4. doi: 10.1080/10428194.2018.1480775.

  426. CHAEKAL OK, van Besien K
    A renaissance for autologous transplantation in follicular lymphoma?
    Leuk Lymphoma. 2018 Jul 3:1-3. doi: 10.1080/10428194.2018.1480777.

  427. ALBANO D, Bosio G, Re A, Pagani C, et al
    Metabolic behavior and prognostic value of early and end of treatment 18F-FDG PET/CT in adult Burkitt's lymphoma: the role of Deauville and IHP criteria.
    Leuk Lymphoma. 2018 Jul 3:1-8. doi: 10.1080/10428194.2018.1482541.
    PubMed     Abstract available

  428. PONTIKOGLOU C, Kalyva A, Kalpadakis C, Velegraki M, et al
    Bone marrow-derived mesenchymal stem/stromal cells from patients with splenic marginal zone lymphoma are intrinsically impaired and influence the malignant B-cells.
    Leuk Lymphoma. 2018 Jul 3:1-3. doi: 10.1080/10428194.2018.1474526.

  429. OLLILA TA, Olszewski AJ
    Radiation therapy in primary testicular lymphoma: does practice match the standard of care?
    Leuk Lymphoma. 2018 Jul 3:1-4. doi: 10.1080/10428194.2018.1480776.

  430. MANNA M, Lee-Ying R, Davies G, Stewart C, et al
    Autologous transplantation improves survival rates for follicular lymphoma patients who relapse within two years of chemoimmunotherapy: a multi-center retrospective analysis of consecutively treated patients in the real world.
    Leuk Lymphoma. 2018 Jul 3:1-9. doi: 10.1080/10428194.2018.1473576.
    PubMed     Abstract available

  431. CHAN H, Moraes FY, Berlin A, Crump M, et al
    Significance of treatment response when managing patients with primary central nervous system lymphoma.
    Leuk Lymphoma. 2018 Jul 3:1-9. doi: 10.1080/10428194.2018.1474524.
    PubMed     Abstract available

  432. HOSSAIN NM, Dahiya S, Le R, Abramian AM, et al
    Circulating tumor DNA assessment in patients with diffuse large B-cell lymphoma following CAR T-cell therapy.
    Leuk Lymphoma. 2018 Jul 3:1-4. doi: 10.1080/10428194.2018.1474463.

  433. SANDOVAL-SUS JD, Faramand R, Chavez J, Puri S, et al
    Allogeneic hematopoietic cell transplantation is potentially curative in mantle cell lymphoma: results from a single institution study.
    Leuk Lymphoma. 2018 Jul 2:1-8. doi: 10.1080/10428194.2018.1468894.
    PubMed     Abstract available

  434. GULATI N, Beguelin W, Giulino-Roth L
    Enhancer of zeste homolog 2 (EZH2) inhibitors.
    Leuk Lymphoma. 2018;59:1574-1585.
    PubMed     Abstract available

  435. STRATI P, Tang G, Duose DY, Mallampati S, et al
    Myeloid/lymphoid neoplasms with FGFR1 rearrangement.
    Leuk Lymphoma. 2018;59:1672-1676.
    PubMed     Abstract available

    June 2018
  436. HUNTINGTON S, Keshishian A, McGuire M, Xie L, et al
    Costs of relapsed diffuse large B-cell lymphoma among Medicare patients.
    Leuk Lymphoma. 2018 Jun 25:1-8. doi: 10.1080/10428194.2018.1459613.
    PubMed     Abstract available

  437. LONTOS K, Tsagianni A, Yuan JM, Normolle DP, et al
    Location matters in early stage nodal diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2018 Jun 22:1-4. doi: 10.1080/10428194.2018.1471600.

  438. WALSHAW RC, Illidge TM
    Revisiting the role of radiotherapy in Hodgkin lymphoma to augment systemic immunity.
    Leuk Lymphoma. 2018 Jun 22:1-2. doi: 10.1080/10428194.2018.1464160.

  439. AGARWAL R, Dawson MA, Dreyling M, Tam CS, et al
    Understanding resistance mechanisms to BTK and BCL2 inhibitors in mantle cell lymphoma: implications for design of clinical trials.
    Leuk Lymphoma. 2018 Jun 18:1-13. doi: 10.1080/10428194.2018.1457148.
    PubMed     Abstract available

  440. CALZADA O, Switchenko JM, Maly JJ, Blum KA, et al
    Deferred treatment is a safe and viable option for selected patients with mantle cell lymphoma.
    Leuk Lymphoma. 2018 Jun 18:1-9. doi: 10.1080/10428194.2018.1455973.
    PubMed     Abstract available

  441. HONG H, Fang X, Wang Z, Huang H, et al
    Angioimmunoblastic T-cell lymphoma: a prognostic model from a retrospective study.
    Leuk Lymphoma. 2018 Jun 18:1-6. doi: 10.1080/10428194.2018.1459610.
    PubMed     Abstract available

  442. ROSWARSKI J, Roschewski M, Lucas A, Melani C, et al
    Phase I dose escalation study of the anti-CD2 monoclonal antibody, siplizumab, with DA-EPOCH-R in aggressive peripheral T-cell lymphomas.
    Leuk Lymphoma. 2018;59:1466-1469.

    May 2018
  443. REICH-SLOTKY R, Makhani SS, Vasovic LV, Pearse RN, et al
    Comparison of time to engraftment between autologous patients receiving washed versus non-washed cryopreserved peripheral blood stem cell products.
    Leuk Lymphoma. 2018 May 23:1-7. doi: 10.1080/10428194.2018.1455975.
    PubMed     Abstract available

  444. ALDERUCCIO JP, Mackrides N, Chapman JR, Vega F, et al
    Rapid complete response to blinatumomab as a successful bridge to allogeneic stem cell transplantation in a case of refractory Richter syndrome.
    Leuk Lymphoma. 2018 May 10:1-4. doi: 10.1080/10428194.2018.1461862.

  445. SETHI TK, Reddy NM
    Treatment of newly diagnosed primary central nervous system lymphoma: current and emerging therapies.
    Leuk Lymphoma. 2018 May 9:1-13. doi: 10.1080/10428194.2018.1466296.
    PubMed     Abstract available

  446. LICATA MJ, Janakiram M, Tan S, Fang Y, et al
    Diagnostic challenges of adult T-cell leukemia/lymphoma in North America - a clinical, histological, and immunophenotypic correlation with a workflow proposal.
    Leuk Lymphoma. 2018;59:1188-1194.
    PubMed     Abstract available

  447. SPINA F, Radice T, De Philippis C, Soldarini M, et al
    Allogeneic transplantation for relapsed and refractory Hodgkin lymphoma: long-term outcomes and graft-versus-host disease-free/relapse-free survival.
    Leuk Lymphoma. 2018 May 1:1-9. doi: 10.1080/10428194.2018.1459607.
    PubMed     Abstract available

  448. FRICK M, Bettstetter M, Bertz S, Schwarz-Furlan S, et al
    Mutational frequencies of CD79B and MYD88 vary greatly between primary testicular DLBCL and gastrointestinal DLBCL.
    Leuk Lymphoma. 2018;59:1260-1263.

    April 2018
  449. LUDMIR EB, Milgrom SA, Pinnix CC, Gunther JR, et al
    Primary breast diffuse large B-cell lymphoma: treatment strategies and patterns of failure().
    Leuk Lymphoma. 2018 Apr 26:1-8. doi: 10.1080/10428194.2018.1460825.
    PubMed     Abstract available

  450. NANNI L, Broccoli A, Nanni C, Argnani L, et al
    Hodgkin lymphoma presenting with paraneoplastic myasthenia: a case report.
    Leuk Lymphoma. 2018 Apr 4:1-4. doi: 10.1080/10428194.2018.1443336.

  451. BEYGI S, Sadashiv S, Reilly JB, Khan C, et al
    Frontline treatment of diffuse large B-cell lymphoma in elderly: a systematic review of clinical trials in post-rituximab era.
    Leuk Lymphoma. 2018 Apr 4:1-15. doi: 10.1080/10428194.2018.1443332.
    PubMed     Abstract available

  452. ZAJA F, Salvi F, Rossi M, Sabattini E, et al
    Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi.
    Leuk Lymphoma. 2018 Apr 4:1-7. doi: 10.1080/10428194.2018.1452208.
    PubMed     Abstract available

  453. PINNIX CC, Wirth A, Milgrom SA, Andraos TY, et al
    Omitting cardiophrenic lymph nodes in the treatment of patients with Hodgkin lymphoma via modified involved-site radiation therapy.
    Leuk Lymphoma. 2018 Apr 4:1-10. doi: 10.1080/10428194.2018.1452211.
    PubMed     Abstract available

  454. VIDAL L, Lando S, Vaxman I, Shochat T, et al
    The effect of R-CHOP dose reduction on overall survival of elderly patients with DLBCL - comparative study.
    Leuk Lymphoma. 2018;59:904-910.
    PubMed     Abstract available

  455. CASTANEDA C, Minton N, Mezo M, Hirsch D, et al
    False-positive pregnancy tests in females of reproductive potential receiving lenalidomide in the United States.
    Leuk Lymphoma. 2018;59:1025-1026.

  456. SCHAFFER M, Chaturvedi S, Davis C, Aquino R, et al
    Identification of potential ibrutinib combinations in hematological malignancies using a combination high-throughput screen.
    Leuk Lymphoma. 2018;59:931-940.
    PubMed     Abstract available

    March 2018
  457. WIGHT JC, Hawkes EA, Berlangieri SU, Khor R, et al
    An abscopal effect may augment PD-1 inhibition in refractory classical Hodgkin lymphoma.
    Leuk Lymphoma. 2018 Mar 23:1-3. doi: 10.1080/10428194.2018.1452217.

  458. ZHANG PP, Ding DZ, Shi B, Zhang SQ, et al
    Expression of TRIM28 correlates with proliferation and Bortezomib-induced apoptosis in B-cell non-Hodgkin lymphoma.
    Leuk Lymphoma. 2018 Mar 23:1-11. doi: 10.1080/10428194.2018.1452207.
    PubMed     Abstract available

  459. DHOLARIA BR, Hammond WA, Roy V, Sher T, et al
    Allogeneic hematopoietic cell transplant for relapsed-refractory, marginal zone lymphoma: a single-center experience.
    Leuk Lymphoma. 2018 Mar 23:1-4. doi: 10.1080/10428194.2018.1452220.

  460. SORIGUE M, Orna E, Sancho JM
    Venous thromboembolism in patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with lenalidomide: a systematic review.
    Leuk Lymphoma. 2018 Mar 21:1-10. doi: 10.1080/10428194.2018.1448085.
    PubMed     Abstract available

  461. JANIGA J, Kentley J, Nabhan C, Abdulla F, et al
    Current systemic therapeutic options for advanced mycosis fungoides and Sezary syndrome.
    Leuk Lymphoma. 2018;59:562-577.
    PubMed     Abstract available

    February 2018
  462. FEUGIER P, Brice P, Maynadie M, Franchi-Rezgui P, et al
    Management of relapsed or refractory follicular lymphoma patients in daily practice - a French non-interventional study.
    Leuk Lymphoma. 2018 Feb 28:1-4. doi: 10.1080/10428194.2018.1434878.

  463. PEIL-GRUN A, Trenker C, Gorg K, Neesse A, et al
    Diagnostic accuracy and interobserver agreement of contrast-enhanced ultrasound in the evaluation of residual lesions after treatment for malignant lymphoma and testicular cancer: a retrospective pilot study in 52 patients().
    Leuk Lymphoma. 2018 Feb 27:1-6. doi: 10.1080/10428194.2018.1439170.
    PubMed     Abstract available

  464. DE LUCA G, Trasarti S, Bizzoni L, Del Giudice I, et al
    Lymphomatoid granulomatosis and large granular lymphocyte leukemia, a rare association of two lymphoproliferative disorders.
    Leuk Lymphoma. 2018 Feb 23:1-4. doi: 10.1080/10428194.2018.1439583.

  465. CASEY N, Fujiwara H, Azuma T, Murakami Y, et al
    An unusual, CD4 and CD8 dual-positive, CD25 negative, tumor cell phenotype in a patient with adult T-cell leukemia/lymphoma.
    Leuk Lymphoma. 2018 Feb 21:1-3. doi: 10.1080/10428194.2018.1439168.

  466. HAN W, Ibarra G, Gupta M, Yin Y, et al
    Elevated GLI3 expression in germinal center diffuse large B cell lymphoma.
    Leuk Lymphoma. 2018 Feb 21:1-3. doi: 10.1080/10428194.2018.1439169.

  467. BURNELLI R, Rinieri S, Rondelli R, Todesco A, et al
    Long-term results of the AIEOP MH'96 childhood Hodgkin's lymphoma trial and focus on significance of response to chemotherapy and its implication in low risk patients to avoid radiotherapy.
    Leuk Lymphoma. 2018 Feb 16:1-10. doi: 10.1080/10428194.2018.1435872.
    PubMed     Abstract available

  468. STECCO A, Buemi F, Iannessi A, Carriero A, et al
    Current concepts in tumor imaging with whole-body MRI with diffusion imaging (WB-MRI-DWI) in multiple myeloma and lymphoma.
    Leuk Lymphoma. 2018 Feb 12:1-11. doi: 10.1080/10428194.2018.1434881.
    PubMed     Abstract available

  469. MARRERO WD, Cruz-Chacon A, Cabanillas F
    Mantle Cell Lymphoma with t(11;22) (q13;q11.2) an indolent clinical variant?
    Leuk Lymphoma. 2018 Feb 7:1-3. doi: 10.1080/10428194.2018.1427863.

  470. THORP BC, Badoux X
    Atrial fibrillation as a complication of ibrutinib therapy: clinical features and challenges of management.
    Leuk Lymphoma. 2018;59:311-320.
    PubMed     Abstract available

  471. GOYAL S, Oak E, Luo J, Cashen AF, et al
    Minimal activity of nanoparticle albumin-bound (nab) paclitaxel in relapsed or refractory lymphomas: results of a phase-I study.
    Leuk Lymphoma. 2018;59:357-362.
    PubMed     Abstract available

    January 2018
  472. VILLA D, Sehn LH
    Double hit lymphoma: do we need a 'double hit' of intensive therapy?
    Leuk Lymphoma. 2018 Jan 25:1-2. doi: 10.1080/10428194.2018.1429606.

  473. PHIPPS C, Lee YS, Ying H, Nagarajan C, et al
    The impact of time from diagnosis to treatment in diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2018 Jan 18:1-6. doi: 10.1080/10428194.2017.1422863.
    PubMed     Abstract available

  474. KOJIMA M, Carreras J, Kikuti YY, Miyaoka M, et al
    A case of diffuse large B-cell lymphoma with MYC gene cluster amplification related to chromothripsis.
    Leuk Lymphoma. 2018 Jan 18:1-5. doi: 10.1080/10428194.2017.1421753.

  475. DRACH J, Huang H, Samoilova O, Belch A, et al
    Efficacy and safety of frontline rituximab, cyclophosphamide, doxorubicin and prednisone plus bortezomib (VR-CAP) or vincristine (R-CHOP) in a subset of newly diagnosed mantle cell lymphoma patients medically eligible for transplantation in the random
    Leuk Lymphoma. 2018 Jan 17:1-8. doi: 10.1080/10428194.2017.1365855.
    PubMed     Abstract available

  476. COLLINS GP, Rueda A, Salles G, von Tresckow B, et al
    Management of Hodgkin lymphoma in the era of brentuximab vedotin: real-world data from five European countries.
    Leuk Lymphoma. 2018 Jan 16:1-8. doi: 10.1080/10428194.2017.1421762.
    PubMed     Abstract available

  477. SONBOL MB, Hilal T, Dueck AC, Rosenthal AC, et al
    A phase 2 study of rituximab, cyclophosphamide, bortezomib and dexamethasone (R-CyBorD) in relapsed low grade and mantle cell lymphoma.
    Leuk Lymphoma. 2018 Jan 10:1-7. doi: 10.1080/10428194.2017.1416368.
    PubMed     Abstract available

  478. DITTUS C, Grover N, Ellsworth S, Tan X, et al
    Bortezomib in combination with dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) induces long-term survival in patients with plasmablastic lymphoma: a retrospective analysis.
    Leuk Lymphoma. 2018 Jan 5:1-7. doi: 10.1080/10428194.2017.1416365.
    PubMed     Abstract available

  479. CRAMER P, Fraser G, Santucci-Silva R, Grosicki S, et al
    Improvement of fatigue, physical functioning, and well-being among patients with severe impairment at baseline receiving ibrutinib in combination with bendamustine and rituximab for relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma in t
    Leuk Lymphoma. 2018 Jan 3:1-10. doi: 10.1080/10428194.2017.1416364.
    PubMed     Abstract available

  480. WEVER CM, Geoffrion D, Grande BM, Yu S, et al
    The genomic landscape of two Burkitt lymphoma cases and derived cell lines: comparison between primary and relapse samples.
    Leuk Lymphoma. 2018 Jan 3:1-16. doi: 10.1080/10428194.2017.1413186.
    PubMed     Abstract available

  481. TOMITA N, Yokoyama M, Yamamoto W, Watanabe R, et al
    The standard international prognostic index for predicting the risk of CNS involvement in DLBCL without specific prophylaxis.
    Leuk Lymphoma. 2018;59:97-104.
    PubMed     Abstract available

  482. RUTHERFORD SC, Stewart EN, Chen Z, Chadburn A, et al
    The eIF4E inhibitor ribavirin as a potential antilymphoma therapeutic: early clinical data<sup/>.
    Leuk Lymphoma. 2018;59:256-258.

  483. WEHKAMP U, Weichenthal M, Klapper W, Schwarz T, et al
    Unilesional locally recurrent lymphomatoid papulosis with variable histological presentation.
    Leuk Lymphoma. 2018;59:262-264.

    December 2017
  484. LAMAR ZS, Dothard A, Kennedy L, Isom S, et al
    Hyperglycemia during first-line R-CHOP or dose adjusted R-EPOCH chemotherapy for non-Hodgkin lymphoma is prevalent and associated with chemotherapy alteration - a retrospective study.
    Leuk Lymphoma. 2017 Dec 18:1-7. doi: 10.1080/10428194.2017.1410889.
    PubMed     Abstract available

  485. ALJOHANI N, Choi SJ, Day AG, Alhejaily A, et al
    Abundant expression of BMI1 in follicular lymphoma is associated with reduced overall survival.
    Leuk Lymphoma. 2017 Dec 18:1-9. doi: 10.1080/10428194.2017.1410883.
    PubMed     Abstract available

  486. ARIMA H, Fujimoto M, Nishikori M, Kitano T, et al
    Prognostic impact of activation-induced cytidine deaminase expression for patients with diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2017 Dec 18:1-11. doi: 10.1080/10428194.2017.1410884.
    PubMed     Abstract available

  487. FU J, Upshaw J, Cohen J, Rodday AM, et al
    Assessing the risk of cardiac toxicity after contemporary treatment for Hodgkin lymphoma: a systematic review.
    Leuk Lymphoma. 2017 Dec 7:1-5. doi: 10.1080/10428194.2017.1406086.

  488. SU C, Nguyen KA, Bai HX, Cao Y, et al
    Disease site as a determinant of survival outcome in patients with primary cutaneous peripheral T-cell lymphoma, unspecified: an analysis of 4057 cases from the US National Cancer Database.
    Leuk Lymphoma. 2017 Dec 7:1-8. doi: 10.1080/10428194.2017.1410886.
    PubMed     Abstract available

  489. BLOMBERY P, Lickiss J, Dickinson M
    The price of success-health economics of personalized diffuse large B-cell lymphoma treatment.
    Leuk Lymphoma. 2017 Dec 7:1-3. doi: 10.1080/10428194.2017.1408088.

  490. CHEN AI, Leonard JT, Okada CY, Gay ND, et al
    Outcomes of DA-EPOCH-R induction plus autologous transplant consolidation for double hit lymphoma.
    Leuk Lymphoma. 2017 Dec 3:1-6. doi: 10.1080/10428194.2017.1406085.
    PubMed     Abstract available

  491. CHENG WY, Zhu YM, Cheng S, Chen YS, et al
    Development of B-cell prolymphocytic leukemia in a patient with splenic diffuse red pulp small B-cell lymphoma.
    Leuk Lymphoma. 2017 Dec 3:1-4. doi: 10.1080/10428194.2017.1405397.

    November 2017
  492. GIULINO-ROTH L, O'Donohue T, Chen Z, Trippett TM, et al
    Outcome of children and adolescents with relapsed Hodgkin lymphoma treated with high-dose therapy and autologous stem cell transplantation: the Memorial Sloan Kettering Cancer Center experience.
    Leuk Lymphoma. 2017 Nov 29:1-10. doi: 10.1080/10428194.2017.1403601.
    PubMed     Abstract available

  493. DREYLING M, Aurer I, Cortelazzo S, Hermine O, et al
    Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations.
    Leuk Lymphoma. 2017 Nov 27:1-15. doi: 10.1080/10428194.2017.1403602.
    PubMed     Abstract available

  494. SARID N, Sherban A, Bendet A, Adam S, et al
    CT findings are highly predictive for perforation in patients with diffuse large B-cell lymphoma involving the intestines.
    Leuk Lymphoma. 2017 Nov 27:1-6. doi: 10.1080/10428194.2017.1403023.
    PubMed     Abstract available

  495. KEMPIN S, Finger PT, Gale RP, Rescigno J, et al
    A cluster of vitreoretinal lymphoma in New York with possible link to the Chernobyl nuclear disaster.
    Leuk Lymphoma. 2017 Nov 22:1-4. doi: 10.1080/10428194.2017.1403025.

  496. KO SH, Lee JH, Lee JH, Park HS, et al
    Allogeneic hematopoietic cell transplantation for lymphoma: baseline and posttransplant prognostic factors.
    Leuk Lymphoma. 2017 Nov 22:1-11. doi: 10.1080/10428194.2017.1399310.
    PubMed     Abstract available

  497. BODY S, Esteve-Arenys A, Recasens-Zorzo C, Troussard X, et al
    A mouse model of disseminated mantle cell lymphoma highlights a lack of activity of estrogen receptor beta agonists toward tumor burden.
    Leuk Lymphoma. 2017 Nov 22:1-4. doi: 10.1080/10428194.2017.1399313.

  498. TAN CRC, Barta SK, Lee J, Rudek MA, et al
    Combination antiretroviral therapy accelerates immune recovery in patients with HIV-related lymphoma treated with EPOCH: a comparison within one prospective trial AMC034.
    Leuk Lymphoma. 2017 Nov 21:1-10. doi: 10.1080/10428194.2017.1403597.
    PubMed     Abstract available

  499. GLEESON M, Peckitt C, Cunningham D, Gibb A, et al
    Outcomes following front-line chemotherapy in peripheral T-cell lymphoma: 10-year experience at The Royal Marsden and The Christie Hospital.
    Leuk Lymphoma. 2017 Nov 9:1-10. doi: 10.1080/10428194.2017.1393671.
    PubMed     Abstract available

  500. MARTINEZ-TRILLOS A, Pinyol M, Delgado J, Aymerich M, et al
    The mutational landscape of small lymphocytic lymphoma compared to non-early stage chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Nov 8:1-9. doi: 10.1080/10428194.2017.1397660.
    PubMed     Abstract available

  501. NEUMANN DR, Marini BL, Phillips TJ, Wilcox RA, et al
    Pegasparaginase silent inactivation during therapy for NK/T cell lymphoma.
    Leuk Lymphoma. 2017 Nov 6:1-10. doi: 10.1080/10428194.2017.1393672.
    PubMed     Abstract available

    October 2017
  502. GREIL C, Ihorst G, Kiote-Schmidt C, Hildenbeutel S, et al
    Stem cell mobilization in poor mobilizers with multiple myeloma or lymphoma before and after introduction of plerixafor: a single-center comparative analysis using a cost-efficient single fixed-dose schedule.
    Leuk Lymphoma. 2017 Oct 30:1-4. doi: 10.1080/10428194.2017.1393673.

  503. ITOH K, Igarashi T, Irisawa H, Aotsuka N, et al
    Randomized phase II study of a bendamustine monotherapy schedule for relapsed or refractory low-grade B-cell non-Hodgkin lymphoma or mantle cell lymphoma (RABBIT-14).
    Leuk Lymphoma. 2017 Oct 30:1-8. doi: 10.1080/10428194.2017.1390233.
    PubMed     Abstract available

  504. BELTRAN BE, Quinones P, Sanchez G, Paredes A, et al
    Primary cutaneous plasmablastic lymphoma in an immunocompetent patient: is it associated with an indolent course?
    Leuk Lymphoma. 2017 Oct 30:1-3. doi: 10.1080/10428194.2017.1393666.

  505. CHEN Q, Staton AD, Ayer T, Goldstein DA, et al
    Exploring the potential cost-effectiveness of precision medicine treatment strategies for diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2017 Oct 25:1-10. doi: 10.1080/10428194.2017.1390230.
    PubMed     Abstract available

  506. ZAGADAILOV EA, Corman S, Chirikov V, Johnson C, et al
    Real-world effectiveness of brentuximab vedotin versus physicians' choice chemotherapy in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplantation in the United Kingdom and Germany.
    Leuk Lymphoma. 2017 Oct 18:1-7. doi: 10.1080/10428194.2017.1382698.
    PubMed     Abstract available

  507. JUSKEVICIUS D, Muller A, Hashwah H, Lundberg P, et al
    Characterization of the mutational profile of 11 diffuse large B-cell lymphoma cell lines.
    Leuk Lymphoma. 2017 Oct 18:1-7. doi: 10.1080/10428194.2017.1387903.
    PubMed     Abstract available

  508. ZHANG C, Amos Burke GA
    Pediatric precursor B-cell acute lymphoblastic leukemia with MYC 8q24 translocation - how to treat?
    Leuk Lymphoma. 2017 Oct 12:1-7. doi: 10.1080/10428194.2017.1387914.
    PubMed     Abstract available

  509. QUNAJ L, Castillo JJ, Olszewski AJ
    Survival of patients with CD20-negative variants of large B-cell lymphoma: an analysis of the National Cancer Data Base.
    Leuk Lymphoma. 2017 Oct 11:1-9. doi: 10.1080/10428194.2017.1387912.
    PubMed     Abstract available

  510. VITAGLIANO O, Trastulli F, Cacace F, Leone S, et al
    Ibrutinib as salvage therapy in mantle cell lymphoma with central nervous system involvement in a pretreated unfit patient.
    Leuk Lymphoma. 2017 Oct 11:1-4. doi: 10.1080/10428194.2017.1387910.

  511. CENCINI E, Puccini B, Rigacci L, Fabbri A, et al
    Radiotherapy plus rituximab as first-line regimen for localized follicular lymphoma.
    Leuk Lymphoma. 2017 Oct 10:1-7. doi: 10.1080/10428194.2017.1387909.
    PubMed     Abstract available

  512. SU C, Nguyen KA, Bai HX, Balaji D, et al
    Comparison of chemoradiotherapy with radiotherapy alone for early-stage extranodal natural killer/T-cell lymphoma, nasal type in elderly patients.
    Leuk Lymphoma. 2017 Oct 5:1-7. doi: 10.1080/10428194.2017.1379078.
    PubMed     Abstract available

  513. JACHIET V, Mekinian A, Carrat F, Grignano E, et al
    Autoimmune manifestations associated with lymphoma: characteristics and outcome in a multicenter retrospective cohort study.
    Leuk Lymphoma. 2017 Oct 3:1-7. doi: 10.1080/10428194.2017.1379075.
    PubMed     Abstract available

    September 2017
  514. ZINTER MS, Melton A, Sabnis AJ, Dvorak CC, et al
    Pulmonary veno-occlusive disease in a pediatric hematopoietic stem cell transplant patient: a cautionary tale.
    Leuk Lymphoma. 2017 Sep 28:1-4. doi: 10.1080/10428194.2017.1382697.

  515. XU ZZ, Shen JK, Zhao SQ, Li JM, et al
    Clinical significance of chemokine receptor CXCR4 and mammalian target of rapamycin (mTOR) expression in patients with diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2017 Sep 27:1-10. doi: 10.1080/10428194.2017.1379077.
    PubMed     Abstract available

  516. KAMRAN SC, Jacene HA, Chen YH, Mauch PM, et al
    Clinical outcome of patients with early stage favorable Hodgkin lymphoma treated with ABVD x two cycles followed by FDG-PET/CT restaging and 20 Gy of involved-site radiotherapy.
    Leuk Lymphoma. 2017 Sep 22:1-7. doi: 10.1080/10428194.2017.1376745.
    PubMed     Abstract available

  517. MAZIARZ RT, Hao Y, Guerin A, Gauthier G, et al
    Economic burden following allogeneic hematopoietic stem cell transplant in patients with diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2017 Sep 21:1-10. doi: 10.1080/10428194.2017.1375100.
    PubMed     Abstract available

  518. HERTING F, Friess T, Umana P, Middleton S, et al
    Chemotherapy-free, triple combination of obinutuzumab, venetoclax and idasanutlin: antitumor activity in xenograft models of non-Hodgkin lymphoma.
    Leuk Lymphoma. 2017 Sep 15:1-4. doi: 10.1080/10428194.2017.1376740.

  519. BENTUR OS, Gurion R, Gafter-Gvili A, Gatt M, et al
    Treatment and prognosis of stage I follicular lymphoma in the modern era - does PET matter?
    Leuk Lymphoma. 2017 Sep 13:1-9. doi: 10.1080/10428194.2017.1375102.
    PubMed     Abstract available

  520. DIMOU M, Roumelioti M, Dimitrakopoulou A, Bitsani C, et al
    High-grade B-cell lymphoma of the peritoneum as a result of transformation of a CD5-negative monoclonal B lymphocytosis population in a patient with myelodysplastic syndrome treated with 5-azacytidine.
    Leuk Lymphoma. 2017 Sep 13:1-4. doi: 10.1080/10428194.2017.1375108.

  521. L'ABBATE A, Iacobucci I, Lonoce A, Turchiano A, et al
    RALE051: a novel established cell line of sporadic Burkitt lymphoma.
    Leuk Lymphoma. 2017 Sep 11:1-4. doi: 10.1080/10428194.2017.1372580.
    PubMed     Abstract available

  522. JIANG L, Si T, Yu M, Zeng X, et al
    The tumor suppressive role of inhibin betaA in diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2017 Sep 7:1-11. doi: 10.1080/10428194.2017.1372574.
    PubMed     Abstract available

  523. ARBOE B, Halgren Olsen M, Duun-Henriksen AK, Gorlov JS, et al
    Prolonged hospitalization, primary refractory disease, performance status and age are prognostic factors for survival in patients with diffuse large B-cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation.
    Leuk Lymphoma. 2017 Sep 4:1-10. doi: 10.1080/10428194.2017.1369061.
    PubMed     Abstract available

  524. RAESS PW, Moore SR, Cascio MJ, Dunlap J, et al
    MYC immunohistochemical and cytogenetic analysis are required for identification of clinically relevant aggressive B cell lymphoma subtypes.
    Leuk Lymphoma. 2017 Sep 3:1-8. doi: 10.1080/10428194.2017.1370547.
    PubMed     Abstract available

  525. CHOWDHRY AK, Fung C, Chowdhry VK, Bergsma D, et al
    A population-based study of prognosis and survival in patients with second primary thyroid cancer after Hodgkin lymphoma.
    Leuk Lymphoma. 2017 Sep 1:1-8. doi: 10.1080/10428194.2017.1369063.
    PubMed     Abstract available

    August 2017
  526. WINTER A, Rybicki L, Shah SN, Jagadeesh D, et al
    Prognostic value of pre-transplant PET/CT in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation.
    Leuk Lymphoma. 2017 Aug 30:1-7. doi: 10.1080/10428194.2017.1369065.
    PubMed     Abstract available

  527. DUVIC M, Bates SE, Piekarz R, Eisch R, et al
    Responses to romidepsin in patients with cutaneous T-cell lymphoma and prior treatment with systemic chemotherapy.
    Leuk Lymphoma. 2017 Aug 30:1-8. doi: 10.1080/10428194.2017.1361022.
    PubMed     Abstract available

  528. MEIGNAN M, Cottereau AS
    Interim PET in lymphoma: from Deauville to Peking criteria. On the road, again....
    Leuk Lymphoma. 2017 Aug 30:1-3. doi: 10.1080/10428194.2017.1368078.

  529. HIEMCKE-JIWA LS, Leguit RJ, Radersma-van Loon JH, Westerweel PE, et al
    Efficacy of ibrutinib in a patient with transformed lymphoplasmacytic lymphoma and central nervous system involvement.
    Leuk Lymphoma. 2017 Aug 29:1-4. doi: 10.1080/10428194.2017.1369074.

  530. PAUL U, Richter J, Stuhlmann-Laiesz C, Kreuz M, et al
    Advanced patient age at diagnosis of diffuse large B-cell lymphoma is associated with molecular characteristics including ABC-subtype and high expression of MYC.
    Leuk Lymphoma. 2017 Aug 25:1-9. doi: 10.1080/10428194.2017.1365851.
    PubMed     Abstract available

  531. EL-GALALY TC, Cheah CY
    Questioning the value of routine imaging for patients with mantle cell lymphoma in first remission.
    Leuk Lymphoma. 2017 Aug 22:1-3. doi: 10.1080/10428194.2017.1365863.

  532. GUIDOT DM, Switchenko JM, Nastoupil LJ, Koff JL, et al
    Surveillance imaging in mantle cell lymphoma in first remission lacks clinical utility.
    Leuk Lymphoma. 2017 Aug 10:1-8. doi: 10.1080/10428194.2017.1361032.
    PubMed     Abstract available

  533. PARIKH A, Gopalakrishnan S, Freise KJ, Verdugo ME, et al
    Exposure-response evaluations of venetoclax efficacy and safety in patients with non-Hodgkin lymphoma.
    Leuk Lymphoma. 2017 Aug 10:1-9. doi: 10.1080/10428194.2017.1361024.
    PubMed     Abstract available

  534. Wendtner C-M, and Gregor M. Current perspectives on the role of chemotherapy in chronic lymphocytic leukemia. Leuk Lymphoma. 2017. http://dx.doi.org/10.1080/10428194.2017.1330474.
    Leuk Lymphoma. 2017 Aug 10:1. doi: 10.1080/10428194.2017.1363546.

  535. RYLAND GL, Jones K, McBean M, Khot A, et al
    Comprehensive genomic characterization dissects the complex biology of a case of synchronous Burkitt lymphoma and myeloid malignancy with shared hematopoietic ancestry.
    Leuk Lymphoma. 2017 Aug 9:1-4. doi: 10.1080/10428194.2017.1361029.

  536. HU B, Younes A, Westin JR, Turturro F, et al
    Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma.
    Leuk Lymphoma. 2017 Aug 9:1-8. doi: 10.1080/10428194.2017.1359741.
    PubMed     Abstract available

  537. BUR H, Haapasaari KM, Turpeenniemi-Hujanen T, Kuittinen O, et al
    Low Rap1-interacting factor 1 and sirtuin 6 expression predict poor outcome in radiotherapy-treated Hodgkin lymphoma patients.
    Leuk Lymphoma. 2017 Aug 8:1-11. doi: 10.1080/10428194.2017.1344840.
    PubMed     Abstract available

  538. KATSUSHIMA H, Fukuhara N, Konosu-Fukaya S, Himuro M, et al
    Does double-hit follicular lymphoma with translocations of MYC and BCL2 change the definition of transformation?
    Leuk Lymphoma. 2017 Aug 3:1-5. doi: 10.1080/10428194.2017.1357172.

  539. ZHANG Y, Fan Y, Ying Z, Song Y, et al
    Can the SUVmax-liver-based interpretation improve prognostic accuracy of interim and posttreatment 18F-FDG PET/CT in patients with diffuse large B-cell lymphoma?
    Leuk Lymphoma. 2017 Aug 3:1-10. doi: 10.1080/10428194.2017.1357171.
    PubMed     Abstract available

  540. JURCZAK W, Ramanathan S, Giri P, Romano A, et al
    Comparison of two doses of intravenous temsirolimus in patients with relapsed/refractory mantle cell lymphoma.
    Leuk Lymphoma. 2017 Aug 3:1-9. doi: 10.1080/10428194.2017.1357175.
    PubMed     Abstract available

    July 2017
  541. PAPIN A, Le Gouill S, Chiron D
    Rationale for targeting tumor cells in their microenvironment for mantle cell lymphoma treatment.
    Leuk Lymphoma. 2017 Jul 31:1-9. doi: 10.1080/10428194.2017.1357177.
    PubMed     Abstract available

  542. SANTIAGO V, Lazaryan A, McClune B, McKenna RW, et al
    Quantification of marrow hematogones following autologous stem cell transplant in adult patients with plasma cell myeloma or diffuse large B-cell lymphoma and correlation with outcome.
    Leuk Lymphoma. 2017 Jul 21:1-9. doi: 10.1080/10428194.2017.1352094.
    PubMed     Abstract available

  543. SHLIAKHTSITSAVA K, Romero SAD, Dewald SR, Su HI, et al
    Pregnancy and child health outcomes in pediatric and young adult leukemia and lymphoma survivors: a systematic review.
    Leuk Lymphoma. 2017 Jul 21:1-17. doi: 10.1080/10428194.2017.1352097.
    PubMed     Abstract available

  544. SANCHEZ-GONZALEZ B, Torres E, Ferraro Rosset MP, Calafell M, et al
    Rituximab subcutaneous in B-cell non-Hodgkin lymphoma: clinical experience in a single center.
    Leuk Lymphoma. 2017 Jul 21:1-3. doi: 10.1080/10428194.2017.1349906.

  545. AMMANN EM, Shanafelt TD, Wright KB, McDowell BD, et al
    Updating survival estimates in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) based on treatment-free interval length.
    Leuk Lymphoma. 2017 Jul 18:1-7. doi: 10.1080/10428194.2017.1349905.
    PubMed     Abstract available

  546. HILL BT, Smith MR, Shelley M, Jagadeesh D, et al
    A phase I trial of bortezomib in combination with everolimus for treatment of relapsed/refractory non-Hodgkin lymphoma.
    Leuk Lymphoma. 2017 Jul 11:1-5. doi: 10.1080/10428194.2017.1347932.
    PubMed     Abstract available

  547. SOUZA BMB, De Vito FB, Calado ML, Silva MV, et al
    Evaluation of the cytotoxic response mediated by perforin and granzyme B in patients with non-Hodgkin lymphoma.
    Leuk Lymphoma. 2017 Jul 6:1-7. doi: 10.1080/10428194.2017.1341978.
    PubMed     Abstract available

    June 2017
  548. LAI C, Roschewski M, Melani C, Pittaluga S, et al
    MYC gene rearrangement in diffuse large B-cell lymphoma does not confer a worse prognosis following dose-adjusted EPOCH-R.
    Leuk Lymphoma. 2017 Jun 22:1-4. doi: 10.1080/10428194.2017.1339882.

  549. KIM J, Song YS, Lee JS, Lee WW, et al
    Risk stratification of diffuse large B-cell lymphoma with interim PET-CT based on different cutoff Deauville scores.
    Leuk Lymphoma. 2017 Jun 20:1-8. doi: 10.1080/10428194.2017.1339877.
    PubMed     Abstract available

  550. CHAO C, Silverberg MJ, Chen LH, Xu L, et al
    Novel tumor markers provide improved prediction of survival after diagnosis of human immunodeficiency virus (HIV)-related diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2017 Jun 13:1-9. doi: 10.1080/10428194.2017.1334121.
    PubMed     Abstract available

    CD4+CD26- lymphocytes are useful to assess blood involvement and define B ratings in cutaneous T cell lymphoma.
    Leuk Lymphoma. 2017 Jun 9:1-10. doi: 10.1080/10428194.2017.1334123.
    PubMed     Abstract available

  552. HORING E, Staiger AM, Lenze D, Horn H, et al
    Burkitt lymphoma and diffuse large B-cell lymphoma: a unique case of a composite lymphoma of different clonal origin.
    Leuk Lymphoma. 2017 Jun 5:1-4. doi: 10.1080/10428194.2017.1330469.

  553. ROBAK T, Huang H, Jin J, Zhu J, et al
    Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study.
    Leuk Lymphoma. 2017 Jun 5:1-8. doi: 10.1080/10428194.2017.1321750.
    PubMed     Abstract available

  554. GAUTAM A, Zhu Y, Ma E, Lee SY, et al
    Brentuximab vedotin consolidation post-autologous stem cell transplant in Hodgkin lymphoma patients at risk of residual disease: number needed to treat.
    Leuk Lymphoma. 2017 Jun 5:1-8. doi: 10.1080/10428194.2017.1324160.
    PubMed     Abstract available

  555. HODKOFF A, Bentley P, Xu X
    Loss of CD3 and TCRgammadelta expression in a relapsed hepatosplenic T-cell lymphoma.
    Leuk Lymphoma. 2017 Jun 2:1-3. doi: 10.1080/10428194.2017.1326033.

  556. HAZAR V, Kesik V, Karasu GT, Ozturk G, et al
    Risk factors predicting the survival of pediatric patients with relapsed/refractory non-Hodgkin lymphoma who underwent hematopoietic stem cell transplantation: a retrospective study from the Turkish pediatric bone marrow transplantation registry.
    Leuk Lymphoma. 2017 Jun 2:1-12. doi: 10.1080/10428194.2017.1330472.
    PubMed     Abstract available

  557. P VASSILAKOPOULOS T, Levidou G, Milionis V, Hartmann S, et al
    Thioredoxin-1, chemokine (C-X-C motif) ligand-9 and interferon-gamma expression in the neoplastic cells and macrophages of Hodgkin lymphoma: clinicopathologic correlations and potential prognostic implications.
    Leuk Lymphoma. 2017 Jun 2:1-13. doi: 10.1080/10428194.2017.1289520.
    PubMed     Abstract available

    May 2017
  558. REBOURSIERE E, Gac AC, Garnier A, Salaun V, et al
    Increased frequencies of circulating and tumor-resident Vdelta1+ T cells in patients with diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2017 May 31:1-9. doi: 10.1080/10428194.2017.1321751.
    PubMed     Abstract available

  559. HESS G, Rule S, Jurczak W, Jerkeman M, et al
    Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus.
    Leuk Lymphoma. 2017 May 30:1-9. doi: 10.1080/10428194.2017.1326034.
    PubMed     Abstract available

  560. FAN Y, Zhang Y, Yang Z, Ying Z, et al
    Evaluating early interim fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography with the SUVmax-liver-based interpretation for predicting the outcome in diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2017 May 23:1-9. doi: 10.1080/10428194.2016.1277384.
    PubMed     Abstract available

  561. NAGAI H, Shimomura T, Takeuchi M, Hanada S, et al
    Phase II study of intensified rituximab induction and maintenance for low grade B cell lymphoma.
    Leuk Lymphoma. 2017 May 16:1-7. doi: 10.1080/10428194.2017.1319054.
    PubMed     Abstract available

  562. XIAO X, Huang H, Chen J, Jiang Y, et al
    Haploidentical hematopoietic stem cell transplantation with myeloablative conditioning regimen could serve as an optional salvage therapy for younger patients with refractory or relapsed aggressive non-Hodgkin lymphoma.
    Leuk Lymphoma. 2017 May 16:1-5. doi: 10.1080/10428194.2017.1317096.

  563. WAGNER-JOHNSTON ND, Lensing S, Noy A, Ratner L, et al
    High frequency of identical clonal immunoglobulin DNA in pre-treatment tumor and plasma from untreated patients with HIV-associated lymphoma: prospective multicenter trial of the AIDS malignancies consortium (AMC 064).
    Leuk Lymphoma. 2017 May 16:1-4. doi: 10.1080/10428194.2017.1317095.
    PubMed     Abstract available

  564. DYSHLOVOY SA, Rast S, Hauschild J, Otte K, et al
    Frondoside A induces AIF-associated caspase-independent apoptosis in Burkitt lymphoma cells.
    Leuk Lymphoma. 2017 May 16:1-11. doi: 10.1080/10428194.2017.1317091.
    PubMed     Abstract available

  565. SUN HL, Atenafu EG, Tsang R, Kukreti V, et al
    Bleomycin pulmonary toxicity does not adversely affect the outcome of patients with Hodgkin lymphoma.
    Leuk Lymphoma. 2017 May 15:1-8. doi: 10.1080/10428194.2017.1307980.
    PubMed     Abstract available

  566. SKAMENE T, Crump M, Savage KJ, Reiman T, et al
    Salvage chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: a subset analysis of the Canadian Cancer Trials Group LY.12 randomized phase 3 study.
    Leuk Lymphoma. 2017 May 15:1-9. doi: 10.1080/10428194.2017.1312379.
    PubMed     Abstract available

  567. GUSS ZD, Madkhali A, Chen Q, Zhang Y, et al
    Intensity-modulated involved-site radiation therapy for non-Hodgkin lymphoma of the head and neck.
    Leuk Lymphoma. 2017 May 9:1-3. doi: 10.1080/10428194.2017.1312388.

  568. HO JC, Dabaja BS, Milgrom SA, Smith GL, et al
    Radiation therapy improves survival in patients with testicular diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2017 May 9:1-12. doi: 10.1080/10428194.2017.1312381.
    PubMed     Abstract available

    April 2017
  569. DRENNAN AC, Rui L
    HiJAKing the epigenome in leukemia and lymphoma.
    Leuk Lymphoma. 2017 Apr 12:1-8. doi: 10.1080/10428194.2017.1312370.
    PubMed     Abstract available

  570. GUPTA NK, Wang CC, Mannis GN, Yu JJ, et al
    Regression of methotrexate-resistant AIDS-related primary central nervous system lymphoma with lenalidomide plus combination anti-retroviral therapy.
    Leuk Lymphoma. 2017 Apr 10:1-4. doi: 10.1080/10428194.2017.1312374.

  571. VALDEZ BC, Li Y, Murray D, Liu Y, et al
    The PARP inhibitor olaparib enhances the cytotoxicity of combined gemcitabine, busulfan and melphalan in lymphoma cells.
    Leuk Lymphoma. 2017 Apr 10:1-12. doi: 10.1080/10428194.2017.1306647.
    PubMed     Abstract available

  572. WASHIO K, Oka T, Abdalkader L, Muraoka M, et al
    Gene expression analysis of hypersensitivity to mosquito bite, chronic active EBV infection and NK/T-lymphoma/leukemia.
    Leuk Lymphoma. 2017 Apr 3:1-12. doi: 10.1080/10428194.2017.1304762.
    PubMed     Abstract available

    Three different hematologists, three different answers: how should we treat concurrent systemic and central nervous system lymphoma?
    Leuk Lymphoma. 2017 Apr 3:1-3. doi: 10.1080/10428194.2017.1307364.

  574. HERLING M, Rengstl B, Scholtysik R, Hartmann S, et al
    Concepts in mature T-cell lymphomas - highlights from an international joint symposium on T-cell immunology and oncology().
    Leuk Lymphoma. 2017;58:788-796.
    PubMed     Abstract available

    March 2017
  575. WU SC, Chapman JR, Vega F, Abrahams N, et al
    Hepatosplenic T-cell lymphoma associated with membranoproliferative glomerulonephritis.
    Leuk Lymphoma. 2017 Mar 28:1-4. doi: 10.1080/10428194.2017.1307358.

  576. EL CHEIKH J, Massoud R, Haffar B, Fares E, et al
    Bendamustine as a bridge to allogeneic transplant in relapsed/refractory Hodgkin lymphoma patients who failed salvage brentuximab vedotin postautologous peripheral blood stem cell transplantation.
    Leuk Lymphoma. 2017 Mar 28:1-3. doi: 10.1080/10428194.2017.1307362.

  577. KOSTOS L, Chai KL, Tam CS, Bazargan A, et al
    The positive effect of deferasirox on erythropoiesis in a patient with a dual diagnosis of myelofibrosis and diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2017 Mar 23:1-4. doi: 10.1080/10428194.2017.1281414.

  578. YOON KA, Kim MK, Eom HS, Lee H, et al
    Adverse prognostic impact of vascular endothelial growth factor gene polymorphisms in patients with diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2017 Mar 22:1-6. doi: 10.1080/10428194.2017.1300893.
    PubMed     Abstract available

  579. BORCHMANN S, von Tresckow B
    Novel agents in classical Hodgkin lymphoma.
    Leuk Lymphoma. 2017 Mar 20:1-12. doi: 10.1080/10428194.2017.1300898.
    PubMed     Abstract available

  580. CEDERLEUF H, Hjort Jakobsen L, Ellin F, de Nully Brown P, et al
    Outcome of peripheral T-cell lymphoma in first complete remission: a Danish-Swedish population-based study.
    Leuk Lymphoma. 2017 Mar 20:1-9. doi: 10.1080/10428194.2017.1300888.
    PubMed     Abstract available

  581. YASUHIRO T, Sawada W, Klein C, Kozaki R, et al
    Anti-tumor efficacy study of the Bruton's tyrosine kinase (BTK) inhibitor, ONO/GS-4059, in combination with the glycoengineered type II anti-CD20 monoclonal antibody obinutuzumab (GA101) demonstrates superior in vivo efficacy compared to ONO/GS-4059 i
    Leuk Lymphoma. 2017;58:699-707.
    PubMed     Abstract available

  582. LADIKOU EE, Kassi E
    The emerging role of estrogen in B cell malignancies.
    Leuk Lymphoma. 2017;58:528-539.
    PubMed     Abstract available

    January 2017
  583. BHATT S, Sarosiek KA, Lossos IS
    Interleukin 21 - its potential role in the therapy of B-cell lymphomas.
    Leuk Lymphoma. 2017;58:17-29.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.